

EXPRESS MAIL LABEL NO. EI 086494813 US

PATENT

Docket No. 1758-4034US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

UTILITY APPLICATION AND APPLICATION FEE TRANSMITTAL (1.53(b))

Box Patent Application
ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the patent application of

Named Inventor(s) and
Address(es):

Conceicao Minetti – 3904 Isbell Street, Silver Spring, MD 20306; Francis Michon – 4401 Rosedale Avenue, Bethesda, MD 20814; Jeffrey K. Pullen – 6928 Garland Lane, Columbia, MD 21045; Maryellen Poldvino-Bodnar – 621 Rolling Dale Road, Annapolis, MD 21401; Shu-Mei Liang – 6627 River Road, Bethesda, MD 20817; and Joseph Y. Tai – 1370 Cinnamon Drive, Port Washington, PA 19034

For: MODIFIED IMMUNOGENIC PNEUMOLYSIN COMPOSTIONS AS VACCINES

Enclosed are:

[X] 80 page(s) of specification, 1 page(s) of Abstract, 8 page(s) of claims

[X] 23 sheets of drawing [] formal [X] informal

[X] 8 page(s) of Declaration and Power of Attorney

[X] Unsigned

[] Newly Executed

[] Copy from prior application

[] Deletion of inventors including Signed Statement under 37 C.F.R. § 1.63(d)(2)

[] Incorporation by Reference: The entire disclosure of the prior application, from which a copy of the combined declaration and power of attorney is supplied herein, is considered as being part of the disclosure of the accompanying application and is incorporated herein by reference.

[] Microfiche Computer Program (Appendix)

[] _____ page(s) of Sequence Listing

[] computer readable disk containing Sequence Listing

[] Statement under 37 C.F.R. § 1.821(f) that computer and paper copies of the Sequence Listing are the same

- ☒ Claim for Priority:- Priority under 35 U.S.C. §119(e) is claimed from Provisional Applications
Serial No. 60/053,306 filed July 21, 1997 and Serial No. 60/073,456
filed February 2, 1998.
- ☐ Certified copy of Priority Document(s)
- ☐ English translation documents
- ☐ Information Disclosure Statement
- ☐ Copy of ____ cited references
- ☐ Copy of PTO-1449 filed in parent application serial No. _____.
- ☐ Preliminary Amendment
- ☒ Return receipt postcard (MPEP 503)
- ☐ Assignment Papers (assignment cover sheet and assignment documents)
- ☐ A check in the amount of \$40.00 for recording the Assignment.
- ☐ Assignment papers filed in parent application Serial No. _____.
- ☐ Certification of chain of title pursuant to 37 C.F.R. § 3.73(b).
- ☐ This is a ☐ continuation ☐ divisional ☐ continuation-in-part (C-I-P) of prior application serial no.
_____ filed _____.
- ☐ Cancel in this application original claims _____ of the parent application before
calculating the filing fee. (At least one original independent claim must be retained for filing
purposes.)
- ☐ A preliminary Amendment is enclosed. (Claims added by this Amendment have been
properly numbered consecutively beginning with the number following the highest numbered
original claim in the prior application.
- ☐ The status of the parent application is as follows:
- ☐ A Petition For Extension of Time and a Fee therefor has been or is being filed in the parent
application to extend the term for action in the parent application until _____.
- ☐ A copy of the Petition for Extension of Time in the co-pending parent application is attached.
- ☐ No Petition For Extension of Time and Fee therefor are necessary in the co-pending parent
application.
- ☐ Please abandon the parent application at a time while the parent application is pending or at a time
when the petition for extension of time in that application is granted and while this application is
pending has been granted a filing date, so as to make this application co-pending.
- ☐ Transfer the drawing(s) from the patent application to this application.

- [X] Amend the specification by inserting before the first line the sentence:
Priority under 35 U.S.C. §119(e) is claimed from Provisional Applications Serial No. 60/053,306 filed July 21, 1997 and Serial No. 60/073,456 filed February 2, 1998, both of which are incorporated herein by reference in their entirety.

I. CALCULATION OF APPLICATION FEE (For Other Than A Small Entity)

	Number Filed		Number Extra	Rate	Basic Fee
Total Claims	30	-20=	10	x\$22.00	\$790.00
Independent Claims	13	- 3=	10	x82.00	\$220.00
Multiple Dependent Claims	<input type="checkbox"/> yes <input checked="" type="checkbox"/> no				
			Additional Fee =	\$270.00	
			Add'l Fee =	NONE	\$


Total: \$ 1830.00

- [] A statement claiming small entity status is attached or has been filed in the above-identified parent application and its benefit under 37 C.F.R. § 1.28(a) is hereby claimed. Reduced fees under 37 C.F.R. § 1.9(F) (50% of total) paid herewith \$ _____.
- [] A check in the amount of \$ _____ in payment of the application filing fees is attached.
- [X] Charge Fee(s) to Deposit Account No. 13-4500. Order No. 1758-4036US2. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- [X] The Assistant Commissioner is hereby authorized to charge any additional fees which may be required for filing this application, or credit any overpayment to Deposit Account No. 13-4500, Order No. 1758-4036US2. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: July 21, 1998

By: 
 Kenneth H. Sonnenfeld
 Registration No. 33,285

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN, L.L.P.
 345 Park Avenue
 New York, New York 10154
 (212) 758-4800
 (212) 751-6849 Facsimile
 FORM: UTL-TRAN.NY
 Rev. 5/21/98

PATENT

Docket No. 1758-4036US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : CONCEICAO MINETTI, ET AL.
Serial No. : TBA Group Art Unit: TBA
Filed : July 21, 1998 Examiner: TBA
For : MODIFIED IMMUNOGENIC PNEUMOLYSIN
COMPOSITIONS AS VACCINES

EXPRESS MAIL CERTIFICATE

Express Mail Label No.: EI 086494813 US

Date of Deposit: July 21, 1998


I hereby certify that the following attached paper(s) and/or fee

1. UTILITY APPLICATION AND APPLICATION FEE TRANSMITTAL (1.53(b)) (3 pages)
2. SPECIFICATION (80 pages); ABSTRACT (1 page); CLAIMS (8 pages)
3. INFORMAL DRAWINGS (23 pages)
4. COMBINED DECLARATION AND POWER OF ATTORNEY (8 pages - unexecuted)
5. RETURN RECEIPT POSTCARD

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to: **Box Patent Application**, Assistant Commissioner for Patents, Washington, D.C. 20231.

Kenneth H. Sonnenfeld

(Typed or printed name of person
mailing paper(s) and/or fee)


(Signature of person mailing paper(s) and/or fee)

CORRESPONDENCE ADDRESS:
MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154
(212) 758-4800
(212) 751-6849 Facsimile

FORM: EXP-MAIL.NY
Rev. 11/13/97

EXPRESS MAIL LABEL NO. EI 086494813 US

PATENT

1758-4036US2

5

UNITED STATES PATENT APPLICATION

10

OF

15

CONCEICAO MINETTI, FRANCIS MICHON, JEFFREY K. PULLEN,
MARYELLEN POLVINO-BODNAR, SHU-MEI LIANG, AND JOSEPH Y. TAI

FOR

20

MODIFIED IMMUNOGENIC PNEUMOLYSIN

COMPOSITIONS AS VACCINES

25

30

35

MODIFIED IMMUNOGENIC PNEUMOLYSIN COMPOSITIONS AS VACCINES

FIELD OF THE INVENTION:

This invention relates to the field of vaccines, and in particular, methods for the production of modified
5 forms of pneumolysin and their use in producing compositions for the immunization of mammals against infections caused by bacteria including *Streptococcus pneumoniae*.

BACKGROUND OF THE INVENTION:

10 *Streptococcus pneumoniae* is the major cause of bacterial pneumonia, bacteremia, meningitis, and otitis media (Baltimore et al. in *Bacterial infections of humans: Epidemiology and control* Evans and Brachman eds, Plenum Press, New York, 1989 pp.525-546; Schuchat et al. *N. Engl.*
15 *J. Med.* 1997, 337, 970-976). Even with appropriate antibiotic therapy, pneumococcal infections have been estimated to result in as many as 40,000 deaths a year in the United States (Fedson et al. *Archives of Internal Medicine* 1994, **154**, 2531-2535; Fiebach et al. *Archives of*
20 *Internal Medicine* 1994, **154**, 2545-2557). In addition, pneumococci have gained increased resistance to penicillin and other antibiotics making the development of an effective vaccine to prevent pneumococcal infections a public health priority (Farr et al. *Archives of Internal*
25 *Medicine* 1995, **155**, 2336-2340). Since the current 23-valent pneumococcal capsular polysaccharide vaccine is ineffective in children less than two years old (Douglas et al. *J Infect Dis* 1983, **148**, 131-137; Leinonen et al.

Pediatric Infectious Disease Journal 1986, **5**, 39-44), numerous groups are developing multivalent conjugate vaccines to prevent otitis media, the major indication in this age group.

5 Pneumolysin (PLY), a sulfhydryl-activated
cytolytic toxin, is produced by all types of *Streptococcus*
pneumoniae (Kancierski et al. *J Clin Microbiol* 1987, **25**,
222-225) and is considered a major virulence factor in
pneumococcal infection (Boulnois *Journal of General*
10 *Microbiology* 1992, **138**, 249-259). Genetically engineered
PLY-negative mutant strains of *S. pneumoniae* have been
shown to be significantly less virulent in mice (Berry et
al. *Microb Pathog* 1992, **12**, 87-93; Berry et al. *Infection*
and Immunity 1989, **57**, 2037-2042). Cytotoxicity of PLY to
15 pulmonary endothelial and epithelial cells is well
demonstrated in vitro (Rubins et al. *Infection and*
Immunity 1992, **60**, 1740-1746). In addition, PLY may be
the principal cause of hearing loss and cochlear damage in
a guinea pig model of pneumococcal meningitis (Winter et
20 al. *Infection and Immunity* 1997, **65**, 4411-4418).

As of 1985, an estimated five million children
under the age of 5 died from pneumonia caused by *S.*
pneumoniae in developing countries each year. *Lancet*
(1985) Sep 28 **2(8457)**:699-701. *S. pneumoniae* employs a
25 number of virulence factors to establish an initial
infection and then produce invasive disease(s). To
prevent systemic infections caused by the various
serotypes of *S. pneumoniae*, immunization of infants and
adults with suitable, cross-reactive vaccines, capable of
30 eliciting safe, effective, and long-lasting immunity, is

needed.

In a prospective study of pneumococcal
colonization and infection in children, it was reported
that pneumococcal serotypes 6, 14, 19, and 23 are the most
commonly carried as well as the most frequent cause of
infection in infants, mainly otitis media (Gray et al. *J.*
Infect. Dis., 1988, 158, 948-955). In addition, it was
recently found that these same strains are more frequent
among the penicillin resistant clinical isolates (Nesin et
al. *J. Infect. Dis.*, 1998, 177, 707-713). Clinical
studies carried out in young infants with a tetravalent
pneumococcal conjugate vaccine including the above types,
report a reduction in the carriage of vaccine-related
strains (Dagan et al. *Infect. Dis. J.*, 1997, 16, 1060-
1064).

Almost all isolates of *S. pneumoniae* exhibit an
external capsule made up of repeating oligosaccharides.
Antigenic differences in the capsular polysaccharides due
to different saccharide sequences are the hallmark of the
different *S. pneumoniae* serotypes. Serotype-specific
capsular polysaccharides are the major contributors to the
virulence of the pneumococcus. Existing anti-pneumococcal
vaccines are formulated from 23 capsular polysaccharides
selected from the 84 serologically distinct types
currently recognized. Unfortunately, these vaccines are
not effective in all populations, especially those of
Asia. A second shortcoming of the current vaccines is
that polysaccharides by themselves are poor immunogens,
especially for infants and the elderly.

Polypeptides expressed by *S. pneumoniae* also

play an important pathogenic role. Some of the defined polypeptides that appear to contribute to the virulence of this organism include pneumolysin, autolysin, neuraminidase, pneumococcal surface polypeptide A (PspA), the 37 kDa polypeptide, adhesion molecules, hyaluronidase, and an IgA1 protease.

Virtually all serotypes of *S. pneumoniae* produce pneumolysin, one of the major virulence factors. This expression by the various *S. pneumoniae* serotypes makes pneumolysin a prime candidate for use in a protective vaccine against pneumococcal infections provided its toxicity can be altered.

Pneumolysin is an intracellular bacterial polypeptide with a molecular weight of approximately 53-kD. (KancIerski et al. (1987) *J. Clin. Microbiol.* **25**:222-225.) It is a member of a family of thiol-activated hemolysins and has various effects on eukaryotic cells. Pneumolysin is known to bind to cholesterol molecules in the eukaryotic membrane, form oligomers, and generate transmembrane pores. It has also been demonstrated that the respiratory burst, chemotactic, and phagocytic functions of polymorphonuclear leukocytes, all of which are critically important for removing invading pneumococci, are severely compromised in the presence of pneumolysin.

Pneumolysin causes both cytolytic and cytotoxic effects, and can stimulate an inflammatory response by the complement activation pathway. Nonspecific activation of complement causes depletion of complement polypeptides and generates nonspecific inflammation. Inoculation of

pneumolysin into lungs of experimental animals causes pneumoniae-like symptoms. However, pre-immunization with pneumolysin is protective for experimental animals upon challenge with pneumococci. Paton et al. (1983) *Infect. Immun.* **40**:548-552.

Because of pneumolysin's immunogenic activity and capacity to elicit a protective response in individuals immunized with it, it has been suggested to use pneumolysin as a component of a vaccine. See PCT/AU89/00539. However, before pneumolysin can be included in vaccines for human use, this toxin must be modified so as to be substantially non-toxic while retaining the capacity to elicit protective antibodies.

Modified pneumolysins devoid of toxic activities are reported to have been generated based on the identification of amino acid regions of pneumolysin thought to have similar functions to related thiol-containing polypeptides. (WO 90/06951). The reported mutations are exclusively in the C-terminal portion of the polypeptide and were generated using targeted mutagenesis techniques. Other mutations, including certain specific amino acids in the N-terminal region have been reported to reduce hemolytic activity. The most significant reduction in hemolytic activity is reported as possibly being a result of histidine modification at position 156. Hill et al. (1994) *Infection and Immunity*, 62, 757-758. No data is provided concerning whether any of these substituted pneumolysins were properly refolded. A single mutation, Thr-172→Ile was reported to be responsible for a pneumolysin with reduced hemolytic activity. However,

anomalous electrophoretic mobility indicates that the protein is incorrectly folded. Lock et al. *Microb. Pathog.* (1996) 21, 71-83.

SUMMARY OF THE INVENTION:

5 This invention provides a novel method for generating and identifying stable, genetically modified, substantially non-toxic, immunogenic pneumolysin polypeptides using random PCR mutagenesis. Modified pneumolysin (pneumolysoid) which can be used as immunogens
10 in a vaccine or can be used as an immunogenic carrier polypeptide for polysaccharide conjugate vaccines against *S. pneumoniae* or other bacterial infections are also provided. The modified pneumolysin polypeptides of this
15 of the toxin's toxic activity, elicit antibodies which are cross-reactive with those elicited by the native toxin.

 This invention also relates to nucleic acid sequences encoding the modified pneumolysins, vectors containing them as well as transformed host cells capable
20 of expressing the nucleic acid molecules of this invention.

 Another embodiment of this invention is polysaccharide-polypeptide conjugate molecules in which the modified pneumolysin of this invention is covalently
25 coupled to bacterial polysaccharide to form the conjugate. Such conjugate molecules are useful as immunogens for eliciting a T cell dependent immunogenic response directed against the bacterial polysaccharide conjugated to the modified pneumolysin.

The invention is further directed to pharmaceutical compositions containing the modified pneumolysin polypeptides of the invention which elicit an immune response.

5 This invention further relates to a method of eliciting the production of antibodies reactive to the modified pneumolysin polypeptides. Such antibodies may be used to elicit both active and passive immunity. The modified pneumolysins of this invention may also be used
10 to identify and isolate reactive antibodies.

 It is therefore an object of this invention to provide genetically stable, modified *S. pneumoniae* pneumolysin polypeptides which have substantially attenuated or absent toxicity while retaining epitopes
15 which cause production of antibodies which also bind the native toxin molecule.

 It is a further object of this invention to provide a method for generating genetically modified pneumolysins (pneumolysoids).

20 It is another object of this invention to provide vaccine preparations comprising a modified pneumolysin polypeptide that can elicit antibodies and induce protective immunity against *Streptococcus pneumoniae* when delivered to a susceptible mammal. Such
25 vaccines may be based on the pneumolysoid itself, or conjugates that comprise one or more bacterial polysaccharides covalently bound to a modified pneumolysin polypeptide of this invention.

BRIEF DESCRIPTION OF THE DRAWINGS:

FIG. 1: Wild-type nucleic acid sequence of type 14 pneumolysin.

FIG. 2: Non-limiting nucleic acid variations of type 14 pneumolysin. The residue position followed by examples of nucleic acid substitutions that attenuate hemolytic activity are: 181, C; 443, A; 583, A or G. The residue position followed by examples of nucleic acid substitutions not observed to attenuate hemolytic activity are: 50, G; 54, T; 98, C; 122, G; 134, C; 137, C; 187, T; 196, T; 248, C; 276, C; 302, C; 305, G; 351, T; 380, A; 382, C; 459, C; 514, G; 558, C; 566, G; 717, A; 764, G; 770, G; 1038, T; 1138, A; 1212, A; 1296, T; 1386, G; 1395, A.

FIG. 3: Amino acid sequence of type 14 pneumolysin.

FIG. 4: Non-limiting amino acid variations of type 14 pneumolysin. The residue position followed by examples of amino acid substitutions that attenuate hemolytic activity are: 61, Pro; 148, Lys; 195, Ile or Val; 243, Arg, Val, Glu, or Ser; 286, Asp; 446, Ser. The residue position followed by examples of amino acid substitutions not observed to attenuate hemolytic activity are: 17, Arg; 18, Asn; 33, Thr; 41, Gly; 45, Ala; 46, Thr; 63, Ser; 66, Tyr; 83, Ser; 101, Thr; 102, Gly; 127, Glu; 128, His; 153, Met; 172, Ala; 189, Arg; 239, Arg; 255, Gly; 257, Gly.

FIG. 5: Map of plasmid pNV-19 containing wild-type pneumolysin nucleic acid sequence. The pNV series of plasmids were derived from pET-24a by cloning in modified pneumolysin nucleic acid sequences.

5 FIG. 6: Diagram showing the positions of the nucleic acid and amino acid substitutions in specific modified pneumolysin polypeptides pNVJ1, pNVJ45, pNVJ20, pNVJ22, pNVJ56, pNV103, pNV207, pNV111, pNV211.

10 FIG. 7: SDS-PAGE showing expression of recombinant pneumolysin following IPTG induction.

FIG. 8: Comparison of polysaccharide dose response of polysaccharide specific IgG following two injections of monovalent or tetravalent pneumococcal pneumolysoid vaccines in mice.

15 FIG. 9: Comparison of polysaccharide-specific IgG following two injections in mice of tetravalent pneumococcal vaccines conjugated to pneumolysoid or tetanus toxoid carriers.

20 FIG. 10: Pneumolysoid-specific IgG elicited by monovalent and tetravalent pneumococcal polysaccharide-pneumolysin vaccines in mice after two injections.

25 FIG. 11: Polysaccharide-specific opsonophagocytic activity elicited by tetravalent pneumococcal PS-pneumolysoid and PS-tetanus toxoid conjugate vaccines in mice after two injections.

FIG. 12: Anti-hemolytic pneumolysoid-specific

activity elicited by monovalent and tetravalent pneumococcal conjugates in mice after three injections.

FIG. 13: Hemolysis Inhibition Assay. Hemolysis titer of wild type pneumolysin upon pre-incubation with the indicated mutants. The bars represent the final hemolytic titer of the wild type tested against erythrocytes pre-treated with the indicated mutants.

FIG. 14: Competitive inhibition ELISA studies between a rabbit polyclonal antibody to wild type PLY and wild type PLY protein using soluble wild type PLY, PLYD mutant pNV207 (A) and PLYD mutant pNV103 (B).

FIG. 15: Fluorescence Spectra of Wild Type Pneumolysin and Mutants. Fluorescence emission spectra of wild type pneumolysin and selected mutants recorded in 10 mM sodium phosphate (pH 7.5) employing an excitation wavelength of 290 nm and monochromator slits of 2 nm. O represents pNV207, • represents pNV111, ◇ represents pNV211, + represents pNV103, and □ represents wild-type.

FIG. 16: (A) Far UV CD spectra of mutant pneumolysin pNV207 (upper chart) and type 14 CPS conjugated mutant pneumolysin pNV207 (lower chart); (B) near UV CD spectra of mutant pneumolysin pNV207 (upper chart) and type 14 CPS conjugated mutant pneumolysin pNV207 (lower chart).

FIG. 17: (A) Tetravalent pneumococcal pneumolysoid pNV207 conjugate vaccine in mice: polysaccharide-specific IgG response over time; (B) tetravalent pneumococcal TT conjugate vaccine in mice:

polysaccharide-specific IgG response over time; (C) monovalent pneumococcal pneumolysoid pNV207 conjugate vaccines in mice: polysaccharide-specific IgG response over time.

5

DETAILED DESCRIPTION OF THE INVENTION:

Pneumolysin is found in virtually all known strains of *S. pneumoniae*. Its broad distribution provides the ability to obtain substantial cross-protection among different *S. pneumoniae* serotypes. This invention provides genetically modified pneumolysin polypeptides which act as toxoids (pneumolysoids) and are therefore useful for eliciting antibodies and for use in vaccines against *S. pneumoniae*. Nucleic acid sequences encoding the modified pneumolysins, vectors and host cells transformed with vectors comprising the nucleic acids encoding the modified pneumolysins are also embodiments of this invention.

The modified pneumolysin polypeptides of this invention in which at least one amino acid is substituted, retain sufficient epitopes to be immunogenic and elicit antibodies which are cross-reactive with wild-type pneumolysin. In addition, the toxicity of such modified polypeptides is sufficiently reduced to allow for their administration to mammals without substantial risk of dangerous side effect.

In an embodiment of this invention, specific modified pneumolysin polypeptides are provided which are covalently bound to polysaccharides to produce conjugates. By conjugating the modified pneumolysin polypeptides of

this invention to different polysaccharides, this invention provides compositions capable of eliciting antibodies to a wide range of serologically distinct pathogens. By selecting the capsular polysaccharide from
5 specific bacteria, this invention can be used to provide immunization against meningococcus, pneumococcus, haemophilus influenzae type b and Group B streptococcus as well as other bacteria.

10 In another embodiment of the invention, genetic modifications in the pneumolysin genome are generated using random mutagenesis techniques.

A. Method For Producing and Identifying Modified Pneumolysin

15 Genetically modified pneumolysin polypeptides of this invention are produced using conventional recombinant methodology (Sambrook *et al.* (1989) *Molecular Cloning: A Laboratory Manual* 2nd ed., Cold Spring Harbor Laboratory Press and Ausubel *et al.* Eds. (1997) *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc.). Minor
20 variant forms of pneumolysin polypeptides have been reported which show high degrees of conservation of amino acid and nucleic acid sequences. See, for example, Mitchell *et al.* (1990) *Nucleic Acid Res.* **18**:4010 which is incorporated herein by reference and which reports that
25 isoleucine at position 153 of pneumolysin of type 1 *S. pneumoniae* is substituted with methionine in type 2. Type 14 which also has isoleucine at position 153 has an asparagine at position 380 rather than an aspartic acid. These variations may also be included among other

substitutions in the nucleic acid and amino acid compositions of this invention which provides modified pneumolysin in which at least one epitope is preserved.

Modified pneumolysin polypeptides are provided by this invention which have reduced or no hemolytic activity compared to the wild-type and retain a sufficient number of epitopes to produce antibodies cross reactive with native or wild-type pneumolysin. Identification of such polypeptides is accomplished by first inserting random mutations into the gene encoding pneumolysin and then screening the expressed polypeptide products for loss or reduction of activity associated with toxicity.

1. Methods Of Modifying Pneumolysin

A novel screening system useful for making and identifying substantially immunogenic, but non-toxic or minimally toxic pneumolysins useful in immunizing against *S. pneumoniae* infections is provided by this invention.

This method comprises two basic steps: (1) random mutagenesis and (2) selection.

Random mutagenesis is one of the suitable techniques for introducing mutations into pneumolysin. Standard mutagenesis methods are suitable for use with this invention. In an embodiment, random PCR is performed in order to randomly incorporate nucleotide changes into the type 14 pneumolysin genome. The subsequent selection will identify desirable changes. This method is applicable with any isolated pneumolysin gene. Preferably, enough of the nucleic acid sequences is identified to enable production of oligonucleotide probes.

Non-limiting examples of such pneumolysin genes are those encoding for type 2 and 14 pneumolysin. The nucleotide sequence encoding type 14 is shown in Fig. 1.

5 PCR, or nucleic acid amplification, is described
in U.S. Patent Nos. 4,183,195, 4,965,188 and 5,176,995,
which are incorporated herein by reference. Generally,
PCR is a method for amplifying one or more specific
nucleic acid sequences wherein each sequence consists of
two separate complementary strands. PCR requires
10 hybridizing each strand with a complementary
oligonucleotide primer. These nucleic acids are templates
for synthesis of complementary strands using primers as
described below. An extension product of each primer is
then synthesized which is complementary to each nucleic
15 acid strand. Next, the extension products are separated
from the templates on which they were synthesized to
produce single stranded molecules. Finally, the single
stranded molecules are again treated with the primers of
the first step under conditions such that an extension
20 product is synthesized for each of the single stranded
molecules produced in the second step. These steps may be
repeated for optimal amplification of the original nucleic
acid and product synthesis.

 PCR mutagenesis involves incorporation of a
25 "mismatch" nucleotide into the growing strand and may be
facilitated by reliance on the high error rate of commonly
used PCR polymerases. Other methods, known in the art for
creating random mutations may also be used such as, for
example chemical mutagenesis (Eichenleub, R. (1979) *J.*
30 *Bacteriol.* **138**:559-566.) Alternatively, the mutagenesis

step may be accomplished by PCR using a "semi-random" process in which either one or both primers include a random series of nucleotides but a portion of one or both primers is complementary and thus "anchored" to at least one known pneumolysin sequences.

"Primers," as that term is used herein, refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of nucleic acid synthesis when placed under conditions in which synthesis of a primer extension product which is complementary to a nucleic acid strand is induced, i.e. in the presence of nucleotides and an inducing agent such as DNA polymerase and at a suitable temperature and pH. The primers are preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare amplification products. Preferably, the primers are oligodeoxyribonucleotides but must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent. The exact lengths of the primers will depend on many factors, including temperature, source of primer and use of the method. The primers typically contain 10 or more nucleotides.

Synthetic oligonucleotide primers may be prepared using any suitable method, such as, for example, the phosphotriester and phosphodiester methods (Narang, S.A. et al. (1979) *Meth. Enzymol.* **68**:90; Brown E.L., et al. (1979) *Meth. Enzymol.* **68**:109) or automated embodiments

thereof. In one such automated embodiment, diethylphosphoramidites are used as starting materials and may be synthesized as described by Beaucauge et al. (1981) *Tetrahedron Let.* **22**:1859-1962. One method for
5 synthesizing oligonucleotides on a modified solid support is described in U.S. Pat. No. 4,458,066 which is incorporated herein by reference.

It is also possible to use a primer which has been isolated from a biological source. One such example
10 may be a restriction endonuclease digest of a large nucleic acid molecule encoding pneumolysin which is sufficiently complementary to hybridize to the pneumolysin sequences. Nucleotide substitutions may also be inserted into primers during chemical synthesis.

It is to be understood that the nucleotide
15 sequences of this invention need not be limited to a single mutation within any given molecule encoding the modified pneumolysin polypeptides. Multiple mutations are also possible when they preserve the immunogenic character
20 of native pneumolysin polypeptide (see Fig. 2), while attenuating or eliminating one or more of its toxic characteristics. Multiple modifications may therefore be included in a single polypeptide molecule (see Fig. 4). Multiple modifications may be useful because they may
25 reduce the likelihood of reversion to the toxic native sequence. However, a preferred embodiment of this invention is single mutations in the nucleic acid sequence which result in single amino acid substitutions.

The random or semi-random PCR products encoding
30 modified pneumolysin, may be cloned into an appropriate

expression vector using standard cloning techniques known in the art.

In an embodiment, the vector includes at least one possible cloning site, at least one antibiotic selection marker gene, transcription promoter and an origin of replication. The vector may be grown in a variety of compatible host cells, allowing a high degree of expression. Preferred hosts include bacteria such as *E. coli*, *B. subtilis* or yeast such as *S. cerevisiae*.

Other eukaryotic cells besides yeast such as mammalian cells may also be used, for example. The cloning plasmid vector/host cell combination may be any compatible vector and host cell. Any suitable expression vector and host cell are acceptable provided they are able to support the expression of the modified pneumolysin. Standard protocols for cloning and expression may be used as described in Ausubel, F.M. et al., eds. (1997) *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc. which is incorporated herein by reference.

2. Screening Of Modified Pneumolysin

Following ligation of the modified pneumolysin nucleotide sequence to the vector in proper reading frame and transformation into the host cell, screening is performed in order to identify cell clones expressing modified pneumolysin polypeptides which have reduced or absent toxicity.

A method for identifying suitably transformed hosts expressing the randomly mutated pneumolysin polypeptide is provided by this invention. Preferred

modified pneumolysin polypeptides will have similar structural features such as size when compared to native pneumolysin. Therefore selection methods which analyze polypeptide size such as SDS-PAGE and gel permeation chromatography maybe used. Transformed hosts expressing modified pneumolysin maybe identified by analyzing the proteins expressed by the host using SDS-PAGE and comparing the gel to an SDS-PAGE gel obtained from the host which was transformed with the same vector but not containing a nucleic acid sequence coding for pneumolysin or modified pneumolysin (the "standard host"). Transformed hosts expressing pneumolysoid will produce a new band when examined by SDS-PAGE and transformed hosts producing a large band corresponding to pneumolysoid can be selected as candidates. The modified pneumolysin polypeptides expressed by these clones may then be screened for hemolytic activity in the cell extracts to identify the modified pneumolysin polypeptides that have attenuated hemolytic activity. Transformed hosts producing non-modified or modified yet active pneumolysin which are toxic can be eliminated by this simple screening step.

Alternatively, modified pneumolysin can be identified by other methods known to those of ordinary skill in the art such as, but not limited to, SDS-PAGE, followed by electroblotting or western blotting analysis, or dot blotting of total cell extracts, or limited proteolysis of the soluble fraction and further analysis of the digests by SDS-PAGE or western blotting.

Factors to be considered in choosing the method

of pneumolysin purification and isolation include whether the modified pneumolysin is present as a soluble protein or whether it becomes insolubilized in inclusion bodies. Although not a general rule, mutations which affect the
5 folding properties of pneumolysin appear to favor its accumulation in inclusion bodies.

Modified pneumolysin which has been identified in the soluble fraction of the cell extracts may be isolated and purified by conventional methods of
10 purification, such as, but not limited to: precipitation of nucleic acids, salt fractionation or capture procedures such as ion exchange chromatography or hydrophobic interaction chromatography. Gel permeation chromatography may be used, particularly as a polishing step, following
15 one of the aforementioned chromatographic procedures. Alternatively, the recombinant modified pneumolysin may be isolated by affinity chromatography, or by procedures used for isolation of thiol-containing proteins, as well as other methods known to those of ordinary skill in the art
20 (Current Protocols in Protein Science, 1995 John Wiley & Sons).

Alternatively, modified pneumolysin derived from the inclusion bodies may be isolated following several inclusion body washes to remove nucleic acids and other
25 bacterial cell wall contaminants. This procedure may include, but is not limited to, washing the pellet with regular buffers, or regular buffers and detergent additives. The protein may be further purified under denaturing conditions by dissolving the washed inclusion
30 bodies in urea or guanidine HCl followed by gel filtration

chromatography. This procedure can be done prior to protein refolding. However, refolding followed by ion-exchange chromatography represents a preferred method to achieve maximal yields of refolded and purified protein.

5 Native pneumolysin can be obtained by the procedure described and used as reference. The hemolytic activity and the migratory or elution profile of the native counterpart can thus be used as reference for the isolation of modified pneumolysins from either the soluble
10 or inclusion body fractions.

 Preferred criteria for selecting clones expressing suitable modified pneumolysin polypeptides include one or more of: (1) modified pneumolysin expression; (2) at or near full length expression (based
15 on a molecular weight of about 53,000 for native pneumolysin); (3) presence of pneumolysoid in the soluble fraction; (4) low hemolytic activity; and (5) high yield of expressed polypeptide.

 Although the inclusion of all the above criteria
20 in a screening protocol would identify the most efficient and likely useful clones expressing a useful modified pneumolysin polypeptide, less efficient clones may also produce modified pneumolysins which are suitable for use in this invention including some that may not be full
25 length, but are sufficiently long to elicit production of antibodies cross-reactive with native pneumolysin and/or function as carrier polypeptides in a polysaccharide-polypeptide conjugate molecule.

 Although the preferred method for identifying
30 desirable clones described above directly assays

characteristics of expressed protein including size and hemolytic activity, other methods such as detecting cross-reactivity with antibodies directed against native pneumolysin or hybridization to nucleic acid probes may also be used. In one embodiment, initial identification of host cell clones transformed with plasmids containing the modified pneumolysin nucleic acid sequences may be performed using standard hybridization analysis as known to those skilled in the art. Probes for modified pneumolysin genes include native pneumolysin nucleic acid sequences or the amplification primers or other primers indicating the presence of the amplified sequences. Preferably such hybridizing probes are 30 to 40 nucleotides in length; more preferable 10 to 20 nucleotides in length. Stringency should be relatively low since probes may be hybridizing to sequences containing altered bases.

A preferred method of hybridization is blot hybridization. See Sambrook et al. (1989) *Molecular Cloning: A Laboratory Manual* 2nd Ed., Cold Spring Harbor Laboratory Press which is incorporated herein by reference, for additional details regarding blot hybridization. A probe can be DNA or RNA and can be made detectable by any of the many labeling techniques readily available and known to the skilled artisan. Such methods include, but are not limited to, radio-labeling, digoxigenin-labeling, and biotin-labeling. A well-known method of labeling DNA is ^{32}P using DNA polymerase, Klenow enzyme or polynucleotide kinase. In addition, there are known non-radioactive techniques for signal amplification

including methods for attaching chemical moieties to
pyrimidine and purine rings (Dale, R.N.K. et al. (1973)
Proc. Natl. Acad. Sci. USA **70**:2238-42), methods which
allow detection by chemiluminescence (Barton, S.K. et al.
5 (1992) *J. Am. Chem. Soc.* **114**:8736-40) and methods
utilizing biotinylated nucleic acid probes (Johnson, T.K.
et al. (1983) *Anal. Biochem.* **133**:125-131; Erickson, P.F.
et al. (1982) *J. Immunol. Methods* **51**:241-49; Matthaei,
F.S. et al. (1986) *Anal. Biochem.* **157**:123-28) and methods
10 which allow detection by fluorescence using commercially
available products. Non-radioactive labeling kits are
also commercially available.

The screening process includes testing of the
pneumolysoid-expressing cells for low hemolytic activity
by methods which are known in the art. (Bernheimer, A.
15 (1988) *Meth. Enzymol.* **165**:213-217.) A micro-assay may be
performed in a 96-well, U-bottom, micro-titer plate, using
an aliquot of culture grown from colonies positive for
pneumolysin (native or modified) expression determined as
20 described above. The aliquots may be extracted and
normalized for polypeptide content. The extracts may
further be centrifuged and the resulting pellet cell
debris and the supernatant analyzed separately. Further
identification of pneumolysoid expression in the
25 supernatant indicates availability in the solubilized
fraction.

Aliquots of the cell lysates may be obtained,
pelleted by centrifugation and the supernatant or pellet
analyzed for activity. Screening the pellets for activity
30 involves solubilization with a denaturant, such as urea,

followed by serial dilutions which are conducted as described for the soluble species. Using this procedure the protein undergoes refolding and activity, if present, can be detected.

5 Negative activity results imply either an inactive refolded polypeptide or an improperly refolded polypeptide. To distinguish between these two conditions, a second screening process can be used. Activity-negative clones are denatured and refolded before loading onto an
10 ion-exchange chromatography column. The mutants which have an elution pattern similar to wild-type pneumolysin can be further analyzed by gel-filtration chromatography and monomeric species with a Stokes radius similar to wild-type pneumolysin are selected.

15 The inserted nucleic acid sequence encoding the modified pneumolysin of selected clone(s) may be sequenced by any of the methods commonly used in the art and the corresponding amino acid sequences deduced.

B. Modified Pneumolysin Polypeptides

20 1. Reduction of hemolytic activity

 The modified pneumolysin polypeptides of this invention are polypeptides that are non-hemolytic or substantially non-hemolytic and still maintain at least one epitope that binds to antibody directed against the
25 native polypeptide. Because such hemolytic activity is associated with the toxicity of pneumolysin, the modified pneumolysins would therefore also be expected to be less toxic than native pneumolysin. The modified pneumolysin

polypeptides of this invention contain at least one mutation relative to *S. pneumoniae* type 14 wild-type pneumolysin (Fig. 3), preferably among the first 257 amino acids beginning from the N-terminus. Modification of as few as one amino acid is required to result in modified pneumolysin polypeptides which have little or insignificant toxicity as determined by hemolytic assay. Thus, substitutions at any one, or more, of positions 61, 148 and 195 may result in polypeptides having reduced hemolytic activity. Preferred substitutions for amino acids 61, 148 and 195 are shown below in Table 1.

Table 1

	Amino Acid Position		
	61	148	195
Wild-type	Ser	Met	Phe
Substitutions	Pro	Lys	Ile/Val

Substitutions at these preferred positions with amino acids other than the preferred ones, for example, those having similar charge at neutral pH, are also within the scope of this invention. Accordingly, substitution of the serine at 61 with hydroxyproline; methionine at 148 with arginine or histidine; phenylalanine at 195 with leucine, glycine or alanine are other non-limiting examples of possible substitutions.

Although single substitutions may be sufficient

to attenuate hemolytic activity, such reduction may also be accomplished by substituting in a single polypeptide specific groups of amino acids. For example, the collective substitution in a single polypeptide of the amino acids at positions 33, 46, 83, 239 and 257 produces polypeptides having characteristics of pneumolysin but with reduced hemolytic activity. Preferred substitutions are shown in Table 2.

Table 2

	Amino Acid Position				
	33	46	83	239	257
Wild-type	Ile	Ile	Leu	Ser	Asp
Substitution	Thr	Thr	Ser	Arg	Gly

10

As with the single substitution, other amino acids in addition to those which are preferred may also be substituted based on the same considerations of charge discussed above with the further non-limiting example that serine and threonine may be substituted for each other, and that other neutral amino acids such as those recited above may be substituted for Asp at 257.

15

It should be understood that besides the substitutions disclosed above, which are effective for reducing or eliminating the hemolytic activity, other substitutions may also be made provided that at least one epitope capable of binding an antibody which binds native pneumolysin is retained. Non-limiting examples of amino

20

acid residues which may be substituted but which alone do not reduce hemolytic activity include those at positions 17, 18, 33, 41, 45, 46, 63, 66, 83, 101, 102, 127, 128, 172, 189, 239, 255 and 257. Examples of substitutions at these positions include, but are not limited to those shown in Table 3. Because these sites are not associated with decreases in hemolytic activity it is expected that these positions may be more freely substituted with less regard to size and charge.

Table 3

		Amino Acid Position								
		17	18	33	41	45	46	63	66	83
Wild-type		Lys	Lys	Ile	Asp	Val	Ile	Thr	Asn	Leu
Substitution		Arg	Asn	Thr	Gly	Ala	Thr	Ser	Tyr	Ser

		Amino Acid Position								
		101	102	127	128	172	189	239	255	257
Wild-type		Ile	Asp	Val	Asn	Thr	Gln	Ser	Lys	Asp
Substitution		Thr	Gly	Glu	His	Ala	Arg	Arg	Gly	Gly

It is to be understood that the amino acid substitutions described above are not exhaustive and that other modified pneumolysin polypeptides identified

according to the methods of this invention are also within its scope.

Single point mutations of the native pneumolysin sequence are preferred because the antigenic nature of the native pneumolysin polypeptide is more likely to be preserved by the single point modified form. Alternatively, a combination of multiple mutations, may be used.

However, multiple mutations are sometimes unpredictable. The mutations, in some cases, may act synergistically to abolish activity or they may be involved in compensation mechanisms during folding. For these reasons, single point mutations are considered to be advantageous.

Although the screening process is based on identifying modified pneumolysin polypeptides which are substantially full-length, this invention also encompasses fragments and truncated forms of the modified pneumolysin polypeptides provided they retain at least one epitope recognized by an antibody which binds to the mature pneumolysin. In addition, it is preferred that such fragments or truncated forms be of sufficient size to produce polysaccharide-polypeptide conjugates which produce a T cell dependent immune response.

The hemolytic activity of the pneumolysoid proteins of this invention may vary over a wide range depending on how the pneumolysoid is actually used. For example, conjugation of a pneumolysoid with reduced hemolytic activity may reduce such activity further to acceptable levels. Conversely, where a pneumolysoid is to be introduced into an individual, unconjugated to another

component or where it may be cleaved, it will be desirable to have the hemolytic activity reduced as close to the minimum detectable level as possible. For such purposes, levels of hemolytic activity between about 0.2% and about 0.5%, or more preferably about 0.2% are suitable. Where some hemolytic activity may be tolerated, or where such activity may be further attenuated by, for example, conjugation to polysaccharide, higher levels of hemolytic activity may be acceptable, i.e. from about 0.5% to about 25%, or more preferably between about 1% and about 10%.

2. Protein structure

Previous studies report that the C-terminus of PLY contains the cell-binding site (Owen et al., 1994 FEMS Microbiol. Let. 121, 217-221). The mutagenesis studies of this invention were focused on the N-terminus which reportedly contains the oligomerization domain. The finding that pre-incubation of erythrocytes with certain mutants abrogated the wild type hemolytic activity in a concentration dependent manner indicates that these mutants are indeed capable of competing with the wild type counterpart for the cell binding site. Since the mutants inhibit wild type activity, these mutants likely retain the structural features of wild-type pneumolysin. The preservation of the cell binding domain in the mutant forms, specifically in the case of pNV103 and pNV207 is significant as these mutants also exhibit the immunological properties of the wild type molecule, as evidenced in ELISA inhibition assays. Moreover, antibodies generated against these mutants possess the

ability to neutralize the hemolytic activity of the wild type counterpart, additional evidence of their native-like structure.

The structural features and integrity of wild type pneumolysin and selected mutants have also been assessed by circular dichroism and fluorescence spectroscopy. These techniques offer the unique advantage of providing both qualitative and quantitative information on the secondary and tertiary structure of these proteins. Wild type pneumolysin is characterized by a high content of β -sheet structure, a prominent feature in the far UV CD spectra of all the mutants selected in the present study. The shape of the spectra and deconvolution analysis are consistent with previous studies on recombinant pneumolysin purified from soluble fractions of *E. coli* which was structurally and functionally equivalent to the native pneumococcal pneumolysin (Mitchell et al., 1989 Biochem. Biophys. Acta 1007, 67-72). Likewise, both the near UV CD and fluorescence spectra are consistent with the native structure containing Trp residues (Morgan et al., 1993 Biochem. J. 296, 671-674) whose side chains are partially exposed to solvent, as evidenced by the emission maximum at ~345 nm upon excitation at 290 nm. The unique near UV CD spectra characterized by a minimum ellipticity at ~280 and a maximum ellipticity at ~290 nm, represents a fingerprint of this (Morgan et al., 1993) and other cytolytins, such as perfringolysin (Nakamura et al., 1995 Biochemistry 34, 6513-6520). As such, this characteristic spectroscopic fingerprint may represent a useful baseline measurement for subsequent evaluation of batch-to-batch

consistency, particularly for those mutants selected as components of vaccine candidates.

C. Nucleic Acid Molecules Encoding Modified Pneumolysin

5 The modified pneumolysin polypeptides of this invention are preferably synthesized by expressing a nucleic acid molecule encoding the modified polypeptide in a host microorganism transformed with the nucleic acid molecule. Accordingly, this invention also encompasses
10 the nucleic acid molecules, including DNA and RNA encoding the modified pneumolysins discussed above.

 The DNA encoding the polypeptides of the invention may be used to express recombinant polypeptide in a wide variety of host cells using a wide variety of
15 vectors. The host cell may be prokaryotic or eukaryotic. DNA for native wild-type pneumolysin may be obtained from natural sources, such as *Streptococcus pneumoniae*, or alternatively synthesized. The wild-type DNA may then be used as the starting material for modification, as
20 described above, to obtain the DNA encoding the modified pneumolysin polypeptides of this invention. Once identified as encoding desirable modified pneumolysin polypeptides, the DNA encoding such polypeptides may then be cloned into various vectors for expression.
25 Alternatively, the genes encoding such polypeptides may also be synthesized in whole or in part.

 In one embodiment, the invention relates to a method of expressing the modified pneumolysin polypeptide in a microorganism wherein the microorganism is

transformed by a vector comprising a gene encoding the modified pneumolysin polypeptide wherein the polypeptide so produced comprises more than about 2% of the total protein expressed in the transformed microorganism. In yet another embodiment, the modified pneumolysin polypeptide expressed comprises more than about 40% of the total proteins expressed in *E. coli*.

Cloning vectors may comprise segments of chromosomal, non-chromosomal and synthetic DNA sequences. Non-limiting examples of some suitable prokaryotic vectors include plasmids from *E. coli*, such as *colE1*, *pCR1*, *pBR322*, *pMB9*, and *RP4*. Prokaryotic vectors also include derivatives of phage DNA such as *M13*, *fd*, and other filamentous single-stranded DNA phages.

The modified pneumolysin polypeptides can be expressed either direct or as fusion constructs. Two non-limiting examples of fusion constructs are Thiofusion and His-Tag which can be isolated and purified by conventional methods. Vectors for expressing proteins in bacteria, especially *E. coli*, are also known. Such vectors include, but are not limited to, *pK233* (or any of the *tac* family of plasmids), *pT7*, and *lambda pSKF*. Examples of vectors that express fusion proteins include the *PATH* vectors described by Dieckmann and Tzagoloff (1985) in *J. Biol. Chem.*

260:1513-1520. These vectors contain DNA sequences that encode anthranilate synthesis (*TrpE*) followed by a polylinker at the carboxy terminus. Two non-limiting examples of fusion constructs are Thiofusion and His-Tag which can be isolated and purified by conventional methods. Other expression vector systems are based on

beta-galactosidase (pEX); maltose binding protein (pMAL); and glutathione S-transferase (pGST) -(see (1988) *Gene* **67**:31 and (1990) *Peptide Research* **3**:167). See Ausubel et al., *supra*.

5 Vectors useful in yeast are also available. Suitable examples are YIp, YRp, YCP, YEp and YLp plasmids. See Ausubel, Id.

10 Suitable vectors for use in mammalian cells are also known. Such vectors include well-known derivatives of SV-40, adenovirus, retrovirus-derived DNA sequences and vectors derived from combination of plasmids and phage DNA. Additional vectors for eukaryotic expression vectors are reported in (e.g., P.J. Southern and P. Berg (1982) *J. Mol. Appln. Genet.* **1**:327-341; S. Subramani et al. (1981) *Mol. Cell. Biol.* **1**:854-864; R.J. Kaufmann and P.A. Sharp (1982) *J. Mol. Biol.* **159**:601-621; R.J. Kaufmann and P.A. Sharp (1982) *Mol. Cell. Biol.* **159**:601-664; S.I. Scahill et al. (1983) *Proc. Natl. Acad. Sci. USA* **80**:4654-4659; G. Urlaub and L.A. Chasin (1980) *Proc. Natl. Acad. Sci. USA* **77**:4216-4220.

25 Examples of preferred vectors are plasmids, and some non-limiting examples of plasmids containing the T7 inducible promotor, include the expression plasmids pET-17b, pET-11a, pET-24a-d(+) and pET-9a, all of which are commercially available from Novagen (565 Science Drive, Madison, Wis. 53711). These plasmids comprise, operatively linked, in sequence, a T7 promoter, optionally a lac operator, a ribosome binding site, restriction sites to allow insertion of the structural gene and a T7 terminator sequence. See, Novagen catalogue (1993) at 36-

30

43.

Useful expression hosts include well-known prokaryotic and eukaryotic cells. Some suitable prokaryotic hosts include, for example, *E. coli*, such as
5 *E. coli* BL21 (DE 3), *E. coli* SG-936, *E. coli* HB 101, *E. coli* W3110, *E. coli* X1776, *E. coli* X2282, *E. coli* DHI, and *E. coli* MRC1, *Pseudomonas*, and *Bacillus*, such as *Bacillus subtilis*, and *Streptomyces*. Suitable eukaryotic cells include yeasts such as *Saccharomyces* and other fungi,
10 insect, animal cells, such as COS and CHO cells, human cells and plant cells in tissue culture.

In a preferred embodiment, *E. coli* strain BL21 (DE3) is employed. The above mentioned plasmids may be transformed into this strain.

15 Selection of *E. coli* transformed with the desired vectors may be accomplished using standard selection protocols involving growth in a selection medium which is toxic to non-transformed cells. For example, *E. coli* is grown in a medium containing a selection agent,
20 e.g. any β -lactam to which *E. coli* is sensitive such as ampicillin. The pET expression vectors provide selectable markers which confer antibiotic resistance to the transformed organism.

High level expression of the modified
25 pneumolysin polypeptide can be toxic in *E. coli*. Surprisingly, this invention allows for selection of modified pneumolysin polypeptides which may be expressed in *E. coli* to a level of at least about 40% of total cellular proteins.

30 Additional nucleotide mutations may be made that

were not identified in the selection process particularly where the translated amino acid is the same as the identified amino acid predicted based on the sequence of the selected clone. In addition, nucleotide changes may be made which encode conservative amino acid substitutions, especially where the identified polypeptides exhibit other amino acid substitutions. Conservative amino acid substitutions are known in the art and represent substitutions of "similar" amino acids. Considerations include, but are not limited to polarity, hydrophobicity, size, and side chain structure.

The modified pneumolysin polypeptides of this invention are polypeptides that are non-toxic or substantially non-toxic and still retain at least one epitope that binds antibody directed at native pneumolysin. The modified pneumolysin of this invention contain at least one mutation relative to wild-type pneumolysin, preferably among the first 257 amino acids of the N-terminus. The modified pneumolysin may be altered in that the amino acid present at one, or more than one, of residue sites 17, 18, 33, 41, 45, 46, 61, 63, 66, 83, 101, 102, 127, 128, 148, 172, 189, 195, 239, 243, 255, 257, 286 or 446 of wild-type pneumolysin are replaced, removed or blocked. As discussed above, additional modifications can be incorporated from other known, modified pneumolysin polypeptides such as those at residue sites 367, 379, 384, 385, 397, 428, 433, 434 or 435 which are disclosed in PCT WO 90/06951 which is incorporated herein by reference. In addition to the amino acid substitutions of this invention disclosed herein, other

amino acid substitutions that have been reported (Hill et al. (1994) *Infection and Immunity* 62, 757-758) for pneumolysin may also be used with this invention provided they allow for refolding of the pneumolysin as determined by the methods described herein. Hill et al. reports four N-terminal region mutations, Arg-31→Cys, Leu-75→Phe, Val-127→Gly and His-156→Tyr that result in 75%, 100%, 75% and 2% hemolytic activity, respectively. They also report four C-terminal region mutations, Ala-432→Val, Trp-433→Arg, Trp-436→Arg and Val-468→Leu that result in 100%, <1%, 50% and 100% hemolytic activity, respectively. However, if any of these mutations result in improperly refolded pneumolysoids, then it is preferred they not be used. The preferred modifications of pneumolysin are those at residue sites 61, 148 or 195 and the most preferred is at residue 195. Additionally, the combination of modifications at sites 33, 46, 83, 239 and 257 is also preferred.

Specific changes may be introduced into the native pneumolysin sequence by any of the methods for site-directed mutagenesis known in the art. In a preferred embodiment, PCR may be performed using oligonucleotide amplification primers encoding the desired nucleotide substitution(s) within their sequence.

Alternatively, the modified pneumolysoid polypeptide may be constructed by chemical synthesis. (Kent et al. *Adv. Exp. Med. Biol.*, 1995, 362, 425-438). Such synthesis can be used to make all or part of a pneumolysoid. In the case of partial synthesis, the

synthetic peptide can be covalently bound to an appropriate portion of the pneumolysoid peptide, prepared by methods known in the art or taught herein, to generate a semi-synthetic pneumolysoid.

5 **D. Vaccine and Antibody Preparations**

 This invention is also directed to vaccine and antibody preparations. According to this invention, the expressed, modified pneumolysin described above or its derivatives or fragments thereof may be used as an
10 immunogen to generate antibodies that are reactive against pneumolysin.

1. Antibodies

 The recombinant techniques for polypeptide expression described above, provide for the production of
15 abundant amounts of the modified pneumolysin polypeptides of this invention, based on the nucleic acid sequences of this invention. This facilitates the generation of antibodies reactive against the modified pneumolysin polypeptide. However, it should be understood that the
20 polypeptide may also be synthesized by chemical methods or combinations thereof.

 In another embodiment, antibodies directed against the modified pneumolysin polypeptides may be generated by any of the techniques that are well known in
25 the art. According to one approach, the antibodies may be generated by injecting an isolated modified pneumolysin polypeptide preparation or derivatives or fragments

thereof into a host animal. The host animal may be, but is not limited to, rat, mouse, rabbit, non-human primate, or a human. Immunological responses may be increased by the use of adjuvants which are known in the art.

5 Monoclonal antibodies directed against the modified pneumolysin polypeptide may also be prepared by any of the techniques that are well known in the art. According to one method, cultures of continuous hybridoma cell lines are used (Kohler and Milstein (1975) *Nature* 10 **256**:495-497). Monoclonal antibodies directed against the modified pneumolysin polypeptide may be human monoclonal antibodies or chimeric monoclonal antibodies made by any of the techniques that are well known in the art. According to one approach, chimeric monoclonal antibodies 15 may be generated that have a non-human (e.g. mouse) antigen-binding domain combined with a human constant region. (Takeda *et al.* (1985) *Nature* **314**:452).

 Antibodies directed against the modified pneumolysin polypeptide may be purified by any of the 20 techniques that are well known in the art including, but not limited to immunoabsorption or immunoaffinity chromatography, or other chromatographic methods (e.g. HPLC, gel filtration or ion exchange). Antibodies may also be purified as immunoglobulin fractions from serum, 25 plasma or cell culture medium.

 Antibody molecules of this invention may be intact immunoglobulin molecules, substantially intact immunoglobulin molecules, or those portions of an immunoglobulin molecule, for example Fab fragments, that 30 contain the antigen binding site.

Fragments of antibodies directed against the modified pneumolysin polypeptide may be generated by any of the techniques that are well known in the art.

(Campbell (1985) *Laboratory Techniques in Biochemistry and Molecular Biology*, Vol. 13, Burdon, et al. (eds.), Elsevier Science Publishers, Amsterdam).

2. Conjugate Molecules

The modified pneumolysin polypeptides of this invention may be used to elicit an antibody response to *S. pneumoniae* in an individual either alone or when conjugated to another immunogenic molecule such as a polysaccharide. The other immunogenic molecule, may be derived from either *S. pneumoniae*, or from a different infectious agent against which it is desirable to generate an immune response. Preferably the other immunogenic molecule to which the modified pneumolysin is conjugated is a capsular or non-capsular polysaccharide from a pathogenic bacteria. Such bacteria including for example: *Haemophilus influenzae* type b; meningococcus group A, B, or C; group B or A streptococcus of various serotypes including group B types Ia, Ib, II, III, V, and VIII; as well as the various serotypes of *S. pneumoniae* preferably types 1-23. *S. pneumoniae* serotypes 3, 4, 6b, 9v, 14, 18c, 19f and 23 are most preferred. Such polysaccharides for use to conjugate pneumolysoid may also be modified themselves in order to be more effective or reduce cross-reactivity to endogenous epitopes. See, for example, Jennings et al. U.S. patents 4,727,136, 5,576,002 and U.S application serial number 08/484,569 which is published as international application

WO 96/40239 which are incorporated herein by reference for modification to group B meningococcal polysaccharides.

Any mode of conjugation may be employed to conjugate the polysaccharide components with the modified pneumolysin polypeptide. A preferred method is that described in U.S. Patent No. 4,356,170, i.e. by introducing terminal aldehyde groups (via oxidation of cis-vicinal hydroxyl groups) into the polysaccharide and coupling the aldehyde groups to the polypeptide amino groups by reductive amination. The polysaccharide and the modified pneumolysin polypeptides are thereby linked through a $-CH_2-NH-$ polypeptide linkage.

It is to be understood, however, that the conjugate vaccines of the invention are not limited to those produced via reductive amination. Thus, the vaccines may also be produced by conjugating the polysaccharide with the modified pneumolysin polypeptide using an adipic dihydrazide spacer, as described by Schneerson, R., et al. (1980) *J. Exp. Med.* **1952**:361-476, and in U.S. Patent No. 4,644,059. Alternatively, the binary spacer technology developed by Merck may be used, as described by Marburg, S. et al. (1986) *J. Am. Chem. Soc.* **108**:5282-5287 or, possibly, the reducing ends methodology.

Conjugate molecules prepared according to this invention typically comprise at least one modified pneumolysin polypeptide of the present invention to which is bound at least one polysaccharide component. Thus, this invention provides the ability to produce conjugate molecules wherein the polypeptide is linked to the

polysaccharide through at least two sites to create cross-linked conjugates.

The vaccines of this invention may provide active or passive immunity. Vaccines for providing active immunity comprise a purified modified pneumolysin polypeptide of this invention. Preferably the polypeptide of this vaccine comprises at least one of the following amino acid substitutions in the wild-type pneumolysin amino acid sequence as shown in Table 1.

In another embodiment of this invention, antibodies directed against the modified pneumolysin polypeptide of this invention may be used as a pharmaceutical preparation in a therapeutic or prophylactic application in order to confer immunity from a host individual to another individual (i.e. to augment an individual's immune response against *S. pneumoniae* or to provide a response in immuno-compromised or immuno-depleted individuals including AIDS patients). Passive transfer of antibodies is known in the art and may be accomplished by any of the known methods. According to one method, antibodies directed against the modified pneumolysin polypeptides or conjugates thereof of this invention are generated in an immunocompetent host ("donor") animal, harvested from the host animal and transfused into a recipient individual. For example, a human donor may be used to generate antibodies reactive against the modified pneumolysin polypeptide or conjugate of this invention, the antibodies transfused in therapeutically or prophylactically effective amounts into a human recipient in need of treatment, thereby conferring

resistance in the recipient against not only the pneumolysin toxin, but against *S. pneumoniae* and a bacteria which bind antibodies elicited by the polysaccharide component if the donor was immunized with a conjugate.

E. Pharmaceutical Compositions

The pharmaceutical compositions of this invention may comprise the modified pneumolysin polypeptides, conjugate molecules comprising the modified polypeptides or compositions comprising antibodies elicited by one of the modified pneumolysin polypeptide compositions of this invention. These pharmaceutical compositions are particularly useful as vaccines.

For eliciting passive immunity, the pharmaceutical composition may be comprised of, polyclonal antibodies or monoclonal antibodies or their derivatives or fragments thereof as described above. The amount of antibody, fragment, or derivative will be a therapeutically or prophylactically effective amount as determined by standard clinical techniques.

The pharmaceutical preparations of this invention may be introduced to an individual by methods known to be effective in the art. Intradermal, intraperitoneal, intravenous, subcutaneous, intramuscular, oral, and intranasal are among, but not the only routes of introduction.

The compositions of the invention may comprise standard carriers, buffers or preservatives known to those in the art which are suitable for vaccines including, but

not limited to any suitable pharmaceutically acceptable carrier, such as physiological saline or other injectable liquids. Additives customary in vaccines may also be present, for example stabilizers such as lactose or sorbitol, and adjuvants to enhance the immunogenic response such as aluminum phosphate, hydroxide, or sulphate and stearyl tyrosine. The vaccines produced according to this invention may also be used as components of multivalent vaccines which elicit an immune response against a plurality of infectious agents.

Vaccines of the present invention are administered in amounts sufficient to elicit production of antibodies as part of an immunogenic response. Dosages may be adjusted based on the size, weight or age of the individual receiving the vaccine. The antibody response in an individual can be monitored by assaying for antibody titer or bactericidal activity and boosted if necessary to enhance the response. Typically, a single dose is about 0.1 to 10 µg/kg.

20 **F. Diagnostic Kits**

In another preferred embodiment, the modified pneumolysin polypeptides of this invention or derivatives or fragments thereof may be used to produce safer diagnostic kits that do not incorporate pneumolysin toxin but can still indicate the presence of antibodies directed against *S. pneumoniae*. The presence of such antibodies can indicate prior exposure to the pathogen, and predict individuals who may be resistant to infection. An antibody reaction may be identified by any of the methods

described in the art, including but not limited to an ELISA assay. Such knowledge is important, and can avoid unnecessary vaccination. The diagnostic kit may comprise at least one of the modified pneumolysin polypeptides of this invention or derivatives or fragments thereof and suitable reagents for the detection of an antibody reaction when the modified polypeptides or derivatives or fragments are mixed with a sample that contains antibody directed against pneumolysin.

Alternatively, the diagnostic kit may further comprise a solid support or magnetic bead or plastic matrix and at least one of the modified pneumolysin polypeptides of this invention or derivatives or fragments thereof.

In some cases, it may be preferred that the polypeptides or derivatives or fragments are labeled. Labeling agents are well-known in the art. For example, labeling agents include but are not limited to radioactivity, chemiluminescence, bioluminescence, luminescence, or other identifying "tags" for convenient analysis. Body fluids or tissues samples (e.g. blood, serum, saliva) may be collected and purified and applied to the diagnostic kit. The pneumolysin polypeptides, derivatives (pneumolysoid) or fragments may be purified or non-purified and may be composed of a cocktail of molecules. Antibodies within the sample may or may not react with the pneumolysin.

Solid matrices are known in the art and are available, and include, but are not limited to polystyrene, polyethylene, polypropylene, polycarbonate,

or any solid plastic material in the shape of test tubes, beads, microparticles, dip-sticks, plates or the like. Additionally matrices include, but are not limited to membranes, 96-well micro titer plates, test tubes and
5 Eppendorf tubes. In general such matrices comprise any surface wherein a ligand-binding agent can be attached or a surface which itself provides a ligand attachment site.

All publications, patents and articles referred to within the specification are herewith incorporated *in*
10 *toto*, by reference into the application. The following examples are presented to illustrate the present invention but are in no way to be construed as limitations on the scope of the invention. One skilled in the art will readily recognize other permutations within the purview of
15 the invention.

EXAMPLES

Materials and Methods

Bacterial Strains and Plasmids. *Streptococcus pneumoniae* serotype 14 (ATCC, Rockville, MD) was used in
20 this study for isolation of genomic DNA. *E. coli* strain DH5 α (Life Technologies, Gaithersburg, MD) was used for initial cloning and production of plasmid DNA. *E. coli* strain BL21 (DE3) Δ ompA, used for protein expression, was derived from BL21 (BE3) (Novagen) (see U.S. Patent No.
25 5,439,808 for details). *S. pneumoniae* was grown overnight in Todd-Hewitt (TH) broth at 37°C without shaking under 7.5% CO₂. *E. coli* strains were grown in Luria-Bertani (LB) broth, supplemented with carbenicillin (50-100 μ g/ml)

or kanamycin (50 µg/ml) as needed. The plasmid vectors pUC-19 and/or pBluescript II SK+ (Stratagene) were used for cloning fragments to be sequenced and the plasmids pET-17b and pET-24a (Novagen) were used for cloning fragments to be expressed.

SDS-PAGE. Protein samples were prepared as follows: 1.5 ml fractions were collected from cultures and the cells harvested by centrifugation. The cells were resuspended in 150 µl of protein loading buffer and boiled for 5 min to lyse the cells. Cell debris were removed by centrifugation and 10 µl of each supernatant were electrophoresed through an 8-16% gradient Tris-glycine "Laemmli" polyacrylamide gel (Novex) along with low molecular weight standards (Bio-Rad). Alternatively, crude extracts prepared for analysis of hemolytic activity were diluted 1:1 with protein loading buffer and 10-15 µl loaded onto the gel. The protein bands were visualized with Coomassie blue staining.

EXAMPLE 1

Expression of pneumolysin.

E. coli strain BL21 (DE3) Δ*ompA* transformed with pET-17b or pET-24a containing the desired gene was grown with moderate aeration at 30°C in LB supplemented with 0.4% glucose and 100 µg/ml of carbenicillin (for pET-17b constructs) or 50 µg/ml of kanamycin (for pET-24a constructs). When the OD₆₀₀ reached 0.6, IPTG was added to a final concentration of 0.4 mM (for pET-17b constructs) of 1 mM (for pET-24a constructs) and the cells were

allowed to incubate for another 2 h for screening, or 5 h for larger scale production. To assay for pneumolysin levels, 1.5 ml aliquots were removed prior to induction and at various time points after induction and examined by SDS-PAGE.

EXAMPLE 2

Cloning of the pneumolysin gene for *Streptococcus pneumoniae* serotype 14.

Genomic DNA was isolated from approximately 0.5 g *Streptococcus pneumoniae* serotype 14 using the method described above. This DNA served as the template for two pneumolysin-specific oligonucleotides in a standard PCR reaction. These oligonucleotides were designed to be complementary to the 5' and 3' flanking regions of the pneumolysin gene from *S. pneumoniae* serotype 2 and to contain XbaI restriction sites to facilitate the cloning of the fragment if desired. The sequence of the forward oligonucleotide was 5' AAC CTT GAT TGA TCT AGA TAA GGT ATT TAT GTT GG 3' and the reverse oligonucleotide had the sequence 5' TCT TTT TGT CTC TAG AAT TCT CCT CTC CTA GTC 3'. The PCR reaction conditions were as follows: 200 ng *S. pneumoniae* type 14 genomic DNA, the two oligonucleotide primers described above at 1 µM of each, 200 µM of each dNTP, PCR reaction buffer (10 mM Tris HCl, 50 mM KCl, pH 8.3), 1.5 mM MgCl₂, and 2.5 units of Taq polymerase, and QS. to 100 µl with dH₂O. This reaction mixture was then subjected to 25 cycles of 95°C for 1 min, 50°C for 2 min and 72°C for 1.5 min. At

the end of the cycling period, the reaction mixture was loaded on a 1.0% agarose gel and the material was electrophoresed for 2 h after which the band at 1.7 kb was removed and the DNA recovered using GeneClean® (Bio 101).
5 This DNA was then digested with XbaI, repurified and ligated to XbaI-digested pUC-19 using T4 DNA ligase. The ligation mixture was used to transform competent *E. coli* DH5α. Recombinant plasmids were identified and sequenced; many were found to have a DNA sequence consistent with
10 that of the gene encoding pneumolysin.

EXAMPLE 3

Expression of the pneumolysin gene in *E. coli*.

Plasmids capable of expressing the mature pneumolysin protein were constructed by amplifying DNA containing the
15 full-length pneumolysin gene (pST20, pST85, or type 14 genomic DNA) with nested oligonucleotides designed to isolate the pneumolysin coding region. The forward oligonucleotide was designed to contain a NdeI site and would install a start codon at the 5' end of the coding
20 region. This primer had the sequence 5' TAT TAG GAG GAG CAT ATG GCA AAT AAA GCA GTA AAT G 3'. The reverse oligonucleotide was designed to contain an XhoI site and had the sequence 5' GGC CTC TTT TTG TCT CGA GCA TTC TCC
25 TCT CCT AGT C 3'. This strategy allowed the cloning of the fragment encoding mature pneumolysin into the NdeI and XhoI sites of either the pET-17b or pET-24a. Standard PCR was conducted using a template containing the entire pneumolysin gene (type 1, 2 & 14) and the two

oligonucleotides described above. This PCR reaction yielded a 1.6 kb product when analyzed on a 1.0% agarose gel. The DNA obtained from the PCR reaction was gel purified and digested with the restriction enzyme NdeI and XhoI. The 1.6 kb product was again gel purified and ligated to NdeI- and XhoI- digested pET-17b or pET-24a using T4 DNA ligase. This ligation mixture was then used to transform competent *E. coli* DH5 α . Colonies that contained the 1.6 kb insert were chosen for further analysis. The DNA from the DH5 α clones was analyzed by restriction mapping and the cloning junctions of the chosen plasmids were sequences. After this analysis, the DNA obtained from the DH5 α clones was used to transform *E. coli* BL21 (DE3) Δ ompA. The transformed bacteria were selected on LB-agar containing 100 μ g/ml of carbenicillin, or 50 μ g/ml of kanamycin when using the pET-24a plasmid. Typically, several clones were screened for their ability to produce the mature pneumolysin protein.

EXAMPLE 4

Random Mutagenesis To Generate Modified Pneumolysin.

A portion of the gene encoding pneumolysin comprising amino acid residues 1-257 was subjected to random mutagenesis using a modification of the technique as described. (Cadwell, R.C. and Joyce, G.F. (1994) *PCR Methods Appl.* **3**:pS136-40; Cadwell, R.C. and Joyce, G.F. (1992) *PCR Methods Appl.* **2**:28-33). An oligonucleotide complementary to the T7 promoter region of the pET-24a plasmid (See, Figure 1a) with the sequence 5'ATT ACG CGA CTC ACT ATA GGG 3' and an oligonucleotide complementary to

a region of the pneumolysin gene around 1250 bp (See Figure 1) with the sequence 5'ATT ACG AAC ATT CCC TTT AGG3' were used to define the region of the gene to be mutated. The random mutagenesis PCR reaction conditions were as follows: purified plasmid pNV-19.2 (100ng), the two oligonucleotide primers described above at 1 μ M of each imbalance dNTP concentrations of 0.2 mM dGTP, 0.2 mM dATP, 1 mM dCTP, and 1 mM dTTP, PCR reaction buffer (19 mM Tris-HCl, 50 mM KCl, pH 8.3), 8.0 mM MgCl₂, 0.5 mM MnCl₂, 6 units Taq polymerase, and QS to 100 μ l with dH₂O. This reaction mixture was then subjected to 40 cycles of 95°C for 1 minute, 40°C for 2 minutes, and 72°C for 3 minutes. After the PCR reaction, fragments were extracted with phenol/chloroform and ethanol precipitated. The fragment was then digested with NdeI and HindIII, gel purified and ligated to pNV-19.2, digested with the same enzymes. The fragments were ligated and subsequently transformed into competent BL21 (DE3) *E.coli*.

EXAMPLE 5

Selection of Modified Pneumolysin Expressing Modified Pneumolysin Devoid of Toxic Effects.

The transformation described by Example 4 resulted in numerous colonies (approximately 10⁴) of which 400 were selected randomly for evaluation. The novel screening method described in this example was used to identify colonies that expressed modified pneumolysin polypeptides with the following characteristics: 1) no hemolytic activity, 2) substantially full-length, 3) partially soluble, and 4) monomeric and refoldable when

isolated from inclusion bodies. This screening method involved the following steps:

(a) testing for presence of low hemolytic activity:

5 A micro-hemolytic assay was used to evaluate the clones. Hemolytic activity-assays were conducted in U-bottom micro titer plates using TBS (Tris-buffered saline, pH 7.4) as an incubation buffer. Following a pre-incubation period of 5 min with 1 mM DTT, twofold serial
10 dilutions were performed and the samples incubated with an identical volume of a 1% suspension of washed sheep erythrocytes (Cappel) resuspended in the same buffer. The reactions were conducted at room temperature as a function of time (kinetic study), and the extent of erythrocyte
15 lysis was monitored by visual inspection. Each clone undergoing evaluation was scored from 0-5. A rank of zero indicated no hemolytic activity while a rank of 4-5 indicated hemolytic activity at wild-type levels or above. Two hundred clones with a score of 0,1,2, were selected
20 and screened again for other desired properties.

(b) testing for expression of full-length pneumolysin polypeptide:

The polypeptide expression assay was carried out in a 96-well format. Colonies with low hemolytic activity
25 were evaluated by SDS-PAGE for the presence of a strong band having a molecular weight of about 53,000 Daltons. Full-length pneumolysin has a molecular weight of about 53 kD. Fifty-eight out of 200 were found positive in this assay. These clones were collected for further selection.

30 (c) testing for expression of modified

pneumolysin polypeptides in the soluble fractions:

Modified pneumolysin polypeptides expressed in both the soluble fraction and inclusion bodies are more likely to be refoldable. Ten ml cultures from 2h IPTG-
5 induced *E. coli* cells harboring plasmids containing mutant pneumolysin sequences lacking or exhibiting reduced hemolytic activity were harvested and resuspended in 1.5 ml of TEN buffer; the cells are lysed by a sequential freezing/thawing/sonication procedure until the
10 supernatant exhibits significant levels of protein, as indicated by the Bradford protein assay, which is indicative of successful lysis. The lysed cell suspension is centrifuged (14,000 rpm/10 min) and aliquots of both, the pellet and supernatant are analyzed by SDS-PAGE. An
15 aliquot of the soluble fraction is tested for hemolytic activity and the hemolytic titer is determined to confirm the reduced activity observed in the kinetic qualitative study conducted in the initial phase of screening. Clones were found that contained soluble, modified pneumolysin
20 polypeptides that had little hemolytic activity.

(d) High yields of refoldable and monomeric, modified pneumolysin polypeptides:

Clones containing soluble pneumolysin are selected for the next step in the screening procedure,
25 which consists of discarding the supernatant by aspiration, washing the pellet with TEN buffer twice, and solubilizing the pellet in 5 ml of 8 M urea prepared in TEN buffer. After sonicating for 2 min, the urea solution is quickly centrifuged to remove aggregates and added
30 dropwise to 45 ml of refolding solution, under constant

stirring at 4 °C. The refolding solution is then loaded onto a 2 ml DEAE-Sepharose-FF column, pre-equilibrated in Buffer A (25 mM Tris.HCl, pH 8.0). The column is washed with Buffer A and the bound protein is eluted with a
5 gradient of 0 to 1 M NaCl. The properly refolded pneumolysin mutant should elute as a single peak between 13 and 20% Buffer B (25 mM Tris.HCl, 1 M NaCl, pH 8.0) similarly to what is observed for the wild-type. The protein peak is further analyzed by HPLC on a Superose 12
10 column and both elution time, aggregate/monomer ratio, and hemolytic activity are evaluated (see Table 4). The selected mutant(s) should present a single monomeric species with a Stokes radius comparable to the wild-type. Five clones (pNVJ1, pNVJ20, pNVJ22, pNVJ45, pNVJ56) with
15 high yields of monomeric modified polypeptides were selected for further analysis including nucleic acid sequencing. The amino and nucleic acid substitutions of these clones are shown in Tables 5A and 6. Throughout the specification and claims, proteins are given the name of
20 the vector that encodes them.

**Table 4. Comparison of Wild-Type (pNV19) And Mutant
Pneumolysin Polypeptides**

Protein	Pure Monomer (mg/L)	HPLC (Elution time)	Hemolytic activity (U/mg)	Activity (% wild type)
pNV19	63	20.1	10 ⁶	100
pNV111	92	19.3	2,555 (9) ¹	0.25
pNVJ22	86	20.7	2,440 (9)	0.24
pNVJ20	90	19.8	1,961 (6)	0.20
pNVJ1	66	20.2	1,536 (2)	0.15
pNVJ45	86	18.7	1,360 (5)	0.14
pNVJ56	104	19.8	2,000 (2)	0.20
pNV211	n.d.	20	1800 (2)	0.18
pNV207	100	20.5	800 (2)	0.08
pNV103	104.7	20	950 (2)	0.10

¹ Numbers in parenthesis indicate number of experiments.

Table 5A: Amino Acid Sequence of Wild-Type (pNV19) Pneumolysin and Modified Forms

	X _{aa17}	X _{aa18}	X _{aa33}	X _{aa41}	X _{aa45}	X _{aa46}	X _{aa61}	X _{aa63}	X _{aa66}	X _{aa83}	X _{aa101}	X _{aa102}	X _{aa127}	X _{aa128}	X _{aa148}	X _{aa172}	X _{aa189}	X _{aa195}	X _{aa239}	X _{aa255}	X _{aa257}
Pnv19	Lys	Lys	Ile	Asp	Val	Ile	Ser	Thr	Asn	Leu	Ile	Asp	Val	Asn	Met	Thr	Gln	Phe	Ser	Lys	Asp
pNVJ1	Arg	Asn	-	-	-	-	Pro	-	Tyr	-	Thr	-	-	-	-	-	-	-	-	-	-
pNVJ45	-	-	-	Gly	-	-	-	-	-	-	-	-	-	-	-	Ala	-	Ile	-	Gly	-
pNVJ20	-	-	-	-	-	-	-	Ser	-	-	-	-	Glu	His	Lys	-	-	-	-	-	-
pNVJ22	-	-	Thr	-	-	Thr	-	-	-	Ser	-	-	-	-	-	-	-	-	Arg	-	Gly
pNVJ56	-	-	-	-	Ala	-	-	-	-	-	-	Gly	-	-	-	-	Arg	Val	-	-	-
pNV103	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Val	-	-	-
pNV207	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Ile	-	-	-
pNV111	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Lys	-	-	-	-	-	-
pNV211	-	-	-	-	-	-	Pro	-	-	-	-	-	-	-	-	-	-	-	-	-	-

- 55 -

Table 5B: Amino Acid Sequence of Modified Pneumolysin Polypeptides

Protein	Mutation	Hemolytic activity
pNV19	wild-type	100%
pNV21	446 P to S	25%
pNV46	286 E to D	12%
pNV22	243 G to R, 446 P to S	<1%
pNV38	243 G to V	<1%
pNV39	243 G to E	<1%
pNV40	243 G to S	<1%
pNV20	243 G to R	<1%

Table 6. Nucleic acid substitutions to the wild-type (pNV19) pneumolysin gene which resulted in dramatically reduced hemolytic activity.

	N ₅₀	N ₅₄	N ₉₈	N ₁₂₂	N ₁₃₄	N ₁₃₇	N ₁₈₁	N ₁₈₇	N ₁₉₆	N ₂₄₈	N ₃₀₂	N ₃₀₅	N ₃₈₀	N ₃₈₂	N ₄₄₃	N ₅₁₄	N ₅₆₆	N ₅₈₃	N ₇₁₇	N ₇₆₄	N ₇₇₀
pNV19	A	G	T	A	T	T	T	A	A	T	T	A	T	A	T	A	A	T	T	A	A
pNVJ1	G	T	-	-	-	-	C	-	T	-	C	-	-	-	-	-	-	-	-	-	-
pNVJ45	-	-	-	G	-	-	-	-	-	-	-	-	-	-	-	G	-	-	A	-	G
pNVJ20	-	-	-	-	-	-	-	T	-	-	-	-	A	C	A	-	-	-	-	-	-
pNVJ22	-	-	C	-	-	C	-	-	-	C	-	-	-	-	-	-	-	-	A	-	G
pNVJ56	-	-	-	-	C	-	-	-	-	-	-	G	-	-	-	-	G	G	-	-	-
pNV103	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	G	-	-	-
pNV207	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	A	-	-	-
pNV111	-	-	-	-	-	-	-	-	-	-	-	-	-	-	A	-	-	-	-	-	-
pNV211	-	-	-	-	-	-	C	-	-	-	-	-	-	-	-	-	-	-	-	-	-

EXAMPLE 6

Site Directed Mutagenesis of Pneumolysin Gene With Single Mutation.

To dissect whether a single mutation or multiple
5 mutations are responsible for the loss of hemolytic
activity in specific peptides (Table 4), each mutation was
introduced into the wild-type allele as a single-site
mutation using oligonucleotide directed mutagenesis.
Table 7 presents the oligonucleotides used to introduce
10 these specific mutations. Polypeptides carrying desired
mutations were identified and their nucleic acid sequences
confirmed. The following polypeptides with single base
changes that resulted in a loss of hemolytic activity from
these site-directed polypeptides were identified (See
15 Table 5A): nucleic acid sequence 103 contains a single
base change at 583 from wild-type T to modified G (195-
Phe→Val); nucleic acid sequence 207 contains a single
base change at 583 from wild-type T to modified A (195-
Phe→Ile); nucleic acid sequence 111 contains a single
20 base change at 443 from wild-type T to modified A (148-
Met→Lys); nucleic acid sequence 211 contains a single
base change at 181 from wild-type T to modified C (61-
Ser→Pro).

The polypeptides shown in Table 5B exhibited
25 poor refolding yields, explaining their reduced hemolytic
activity. Single mutations introduced into pneumolysin
polypeptide at positions 243, 286 and 446 or a combination
of substitutions introduced at positions 243 and 446
produced species found exclusively in the insoluble

fraction as inclusion bodies. Attempted refolding of these mutants yielded mostly aggregated species.

Table 7. Modified Pneumolysin Sequences

MUTATION POSITION	AA #	Primer Sequence
443	148	Forward 5'ggtcagggtcaataatgtcccagctagaaAgcagtatg 3'
	Met-Lys	Reverse 5'gctgtgagccgtgattttttcatactgcTttctagctg 3'
583	195	Forward 5'gcagattcagattgttaatGttaagcagatttattata 3'
	Phe-Ile	Reverse 5'atctgcttaaCattaacaatctgaatctgcttttcgcc 3'
583	195	Forward 5'cagattgttaatAttaagcagatttattatacagtcagc3'
	Phe-Val	Reverse 5'aatctgcttaaTattaacaatctgaatctgcttttcgcc3'
181	61	Forward 5'acaagtgatattCctgtaacagctaccaacgacagtcgc3'
	Ser-Pro	Reverse 5'agctgttacagGaatatcacttgtatttgtcgacaagct3'

5

EXAMPLE 7

Expression and Purification of Modified Polypeptides.

These single mutated genes were cloned into expression vectors (pET-24a) individually to overexpress the modified polypeptides in *E. coli*. The expression level is ~40%. Novel purification and refolding processes were developed to purify these recombinant modified

pneumolysins.

Pneumolysin expressed in *E. coli* cells harboring the expression vector pNV19 was isolated from inclusion bodies by resuspending and lysing the cells in TEN buffer (50 mM Tris-HCl, 100 mM NaCl, 10 mM EDTA pH 8.0), with an air driven cell disrupter (Stansted Fluid Power Ltd.) under a pressure of 8,000 psi. The cell lysate was centrifuged at 13,000 rpm at 4°C for 20 minutes; both pellet and supernatant were saved for isolation of soluble and aggregated pneumolysin, respectively. The inclusion bodies were washed three times with TEN buffer and stored at -70°C. Purification and subsequent refolding were achieved by solubilizing the inclusion bodies in an 8 M urea solution (freshly prepared in TEN buffer), followed by PEG-assisted refolding. Polypeptide solutions in 8 M urea (200 µg/ml) were diluted 10-fold by drop-wise addition to a refolding solution, consisting of 20 µM of PEG 8,000 in 25 mM Tris-HCl, pH 8.0, under constant stirring at 4°C. The sample was clarified and loaded into a DEAE-Sepharose Fast Flow ion exchange column (Pharmacia) equilibrated in 25mM Tris-HCl, pH 8.0. A gradient of 0-1 M NaCl was applied and pneumolysin containing fractions were identified by detection of hemolytic activity, as described below, and by SDS-PAGE. The purified fractions were concentrated by using an Amicon concentrator and PM30 membrane. Aliquots of purified polypeptide were tested for hemolytic activity, and analyzed by SDS-PAGE and size exclusion chromatography, using a Superose 12 column.

Hemolytic activity assays were conducted in U-

bottom micro-titer plates using TBS (Tris buffered saline, pH 7.4) as an incubation buffer. Following a pre-incubation period of 5 minutes with 1 mM DTT, twofold serial dilutions of normalized proteins were performed and the samples incubated with an identical volume of a 1% suspension of washed sheep erythrocytes (total volume 200 μ l) (Cappel) resuspended in the same buffer. The reactions were conducted at 37°C for 30 minutes and the extent of erythrocyte lysis was monitored spectrophotometrically by spinning down the U-plates transferring the supernatant to flat-bottomed plates and measuring the extent of hemoglobin release at 450 nm. The end point was set to be the concentration at which 50% lysis occurred and was based on comparison with a 0.5% cell suspension that was lysed hypotonically (see Tables 4 and 5B).

Another method of assaying the modified pneumolysin polypeptides is to conduct a hemolysis inhibition assay of the modified polypeptides. This assay consists of determining the ability of the mutant proteins to reduce or eliminate the hemolytic activity of the wild-type protein by pre-incubating erythrocytes with the modified pneumolysin polypeptides and assessing the hemolytic titer of the wild-type pneumolysin toward the pre-treated erythrocytes. The results from using this assay with four modified polypeptides are given in Table 8, and a detailed description of the procedure appears in Example 11.

Table 8. Hemolysis inhibition assay of pneumolysin by the pneumolysin mutants

	Designation	Mutation	End point (*)
5	pNV19	wild-type	512
	pNV103	Phe ¹⁹⁵ Val	64
	pNV111	Met ¹⁴⁸ Lys	128
	pNV207	Phe ¹⁹⁵ Ile	32
10	pNV211	Ser ⁶¹ Pro	512

(*) Reciprocal of the hemolytic titer of a wild-type pneumolysin preparation in the presence of the indicated mutant

15 The antigenic cross-reactivity of the selected single site pneumolysin mutants was determined by immunizing rabbits (n=2) with each of the mutant proteins shown in Table 9 by conventional immunization procedures. Immunization of rabbits: New Zealand White rabbits

20 (Covance, Denvers, PA) weighing 2-3 kg were immunized subcutaneously with 100 µg of wild-type or mutant pneumolysin emulsified with complete Freund's adjuvant, (Vol/Vol). Booster doses of vaccine mixed with incomplete

25 and 42 days after the primary dose. Sera were collected on day 0, 21, 42, and 52. The sera were tested for the presence of antibodies against wild-type pneumolysin. The antigenic titer of pooled sera (n=2) towards type 14

30 pneumolysin was determined by ELISA. In brief, plates were coated with wild-type pneumolysin and incubated with

serial dilutions of each of the anti-mutant pneumolysin sera. Significant binding of wild-type pneumolysin to antibodies elicited by the modified pneumolysin polypeptides was observed as shown in Table 9.

5

Table 9. Reactivity and hemolysis neutralizing titer of mutant pneumolysin rabbit antisera towards type 14 pneumolysin by ELISA

Designation	Mutation	Titer	Antibody Neutralizing Titer
pNV19	wild-type	892,647	256
pNV211	Ser ⁶¹ Pro	432,100	128
pNV111	Met ¹⁴⁸ Lys	296,113	128
pNV103	Phe ¹⁹⁵ Val	2,505,208	512
pNV207	Phe ¹⁹⁵ Ile	402,426	128
PBS	-	-	8

As can be seen in Table 9, antisera to each of the above polypeptides, in addition to their strong cross-reaction with the wild-type pneumolysin as measured by
10 ELISA, have significant neutralizing, anti-hemolytic titers as measured in a hemolysis inhibition assay.

EXAMPLE 8

Preparation of Pneumolysoid Conjugates Preparation of polysaccharide for conjugation.

5 PnC type 14 polysaccharide (ATCC Lot #2016107)
(390 mg) was dissolved in 16 ml of 0.5 N NaOH, and the
solution was heated at 70°C for 3 hours. Following
cooling of the solution, 1.93 ml of glacial acetic acid
was added to bring the pH to 4. After addition of 3 ml of
10 5% (w/v) NaNO₂, the reaction mixture was kept stirring at
4°C for 2 hours. The sample was then diluted to 50 ml
with deionized water and the pH was adjusted to 7 with 0.5
N NaOH. Excess reagents were dialyzed out by
diafiltration with DI water through a Spectra/Por
15 molecularporous membrane tubing (MWCOL:3,500), and the
retentates freeze-dried. The deaminated type 14
polysaccharide was then molecular sieved on a Superdex G-
200 (Pharmacia) column using PBS as eluent. Fractions
eluting from the column with molecular weight between 5000
20 and 15,000 as determined by Chromatography/Multiangle
Laser Light Scattering using a Superose 12 column
(Pharmacia) were pooled and dialyzed against DI water
through a Spectra/Por molecularporous membrane tubing
(MWCOL 3,500) and freeze-dried.

25 Preparation of conjugates.

Each of the PnCPS were first depolymerized and
functional aldehydes were introduced into the fragmented
CPS by oxidation with sodium metaperiodate. Following the
oxidation process, the excess periodate was destroyed with

ethylene glycol, the oxidized polysaccharides were dialysed against DI water and lyophilized.

Modified pneumolysin polypeptides in 0.2 M phosphate buffer (pH 8) at a concentration of 5 mg/ml were
5 mixed with 2.5 equivalents (by weight) of PnC 14 polysaccharide-fragment together with 2 equivalents (by weight) of recrystallized sodium cyanoborohydride. Reaction mixtures were incubated at 37°C for 24 hours. Conjugates were then purified from the free components by
10 passage through a Superdex G200 (Pharmacia) column using PBS containing 0.01% thimerosal as an eluent. Fractions eluting from the column were monitored on a Waters R403 differential refractometer and by UV spectroscopy at 280 nm. The fractions containing the conjugates were pooled,
15 sterile-filtered through a 0.22 µm Millipore membrane and then stored at 4°C. Polypeptide and carbohydrate content were measured by the methods of Bradford and Dubois respectively. Polysaccharide content in the resulting conjugates were approximately 30%.

20 Tetanus toxoid conjugates for use as control, were also produced as described above and as follows: Tetanus toxoid (Serum Statens Institute) was first passed through a molecular sieve column (Superdex G-200 Pharmacia) in order to obtain the monomer form of the
25 toxoid. For conjugation, 12 mg of the monomer and 36 mg of the PnC 14 polysaccharide-fragments were dissolved in 600 µl of 0.2 M phosphate buffer pH 7.2. Recrystallized sodium cyanoborohydride (24 mg) was then added to the solution which was then incubated at 37°C for 3-days. The

conjugate was purified as above. The conjugates had polysaccharide contents in the 25-30% range (see Table 10).

Table 10.

Composition of Tetanus-Toxoid and Modified Pneumolysin type 14 Conjugates

Carrier Polypeptide	Approx. MW of PS	Polypeptide (mg/ml)	PS (mg/ml)	%PS in Conjugate
pNV103 #195 Phe-Val	9,000	0.170	0.079	32%
pNV207 #195 Phe-Ile	9,000	0.117	0.048	29%
pNV111 #148 Met-Lys	9,000	0.145	0.062	30%
pNV19 Wild-type	9,000	0.115	0.049	30%
Tetanus Tm	9,000	0.245	0.098	28%

5

EXAMPLE 9

Immunization with Modified Pneumolysin Conjugates.

Groups of 20 CD1 female mice (age 6-8 weeks), from Charles River Laboratories, were immunized subcutaneously (S.C.) with 2 µg of the conjugated polysaccharides of Example 8 adsorbed on aluminum (Aluminum hydroxide, Superfos, Denmark) at a concentration of 1 mg of elemental aluminum per ml of PBS containing 0.01% thimerosal. Mice received the vaccine at day 0, 28,

and 49. Sera were collected at day 0, 42, and 59, and stored at -70°C.

ELISA.

Micro titer plates (Nunc Polysorb ELISA plates) were sensitized by adding 100 µl of type 14 polysaccharide-fragment (MW ca: 10,000)/HSA conjugate (2.5 µg/ml) in PBS. The plates were sealed and incubated at 37°C for 1 hour. The plates were washed with PBS containing 0.05% Tween 20 (PBS-T) and blocked with 0.5% (w/v) BSA in PBS for 1 hour at room temperature. The wells were then filled with 100 µl of serial two-fold dilutions in PBS-T plates, 100 µl of peroxidase labeled goat anti-mouse IgG (H+L) (Kirkegaard and Perry Laboratories), and then washed five times with PBS-T. Finally, 50 µl of TMB peroxidase substrate (Kirkegaard and Perry Laboratories) were added to each well, and following incubation of the plates for 10 minutes at room temperature, the reaction was stopped by the addition of 50 µl of 1 M H₃PO₄. The plates were read at 450 nm with a Molecular Device Amex microplate reader using 650 nm as a reference wavelength.

Inhibition ELISA assay.

Microtiter plates (NUNC Polysorp) were coated with PLY (20 ng in 100 µL to each well) in PBS (50 mM sodium phosphate, 150 mM NaCl, pH 7.4) for one hour at 37°C. After washing the plates with PBS + 0.05% Tween 20 (PBST), the plates were post-coated with 150 µL of PBS + 0.1% BSA, rewashed, and stored at 4°C until used.

Hyperimmune rabbit anti-PLY was diluted in PBST, added to the PLY coated plates, and incubated at room temperature for 1 h. After washing, 100 μ L of goat anti-rabbit Ig-HRP conjugate (KPL) diluted in PBSTween according to the manufacturer's instructions were added to each well. The plate was incubated at room temperature for one hour and then washed again. 100 μ L of TMB microwell substrate (KPL) were added to each well. The reaction was stopped after 10 minutes by the addition of TMB one-component stop solution (KPL) and the OD_{450 nm} was immediately read. The dilution corresponding to 1/2 the maximum signal was chosen for the inhibition study. PLYD mutants as well as PLY as a control were diluted serially in three-fold ingrements in PBST containing the rabbit antiserum diluted such that the final mixture contained the dilution which gave half-maximal activity and applied immediately to the coated microtiter plates in duplicate. The plates were incubated at room temperature for one hour and processed. Inhibition was determined as percent of maximum signal achieved with dilute antiserum in the absence of any inhibitor.

Opsonic activity of conjugate antisera.

The opsonic ability of mice antisera to the PnC type 14 conjugates was tested in an *in vitro* opsonophagocytic killing assay using the human promyelocytic leukemia HL-60 cell line (ATCC #CCL240). (See Table 11). Briefly, 200 cfu of PnC type 14 (12-8-95 CB) cells were mixed in equal volume with serially diluted antibodies and incubated 15 minutes under shaking at 37°C

in a 5% CO₂ incubator. Baby rabbit complement and HL-60 cells (5×10^5) cultured 5-days in the presence of 90 mM dimethylformamide were added to the mixture which was then incubated at 37°C for 1 hour under shaking. Aliquots were removed for quantitative culture and plated on chocolate agar. Titers were determined by extrapolating the antibody dilution corresponding to 50% live bacteria.

Table 11. Immunogenicity of PnC 14 Polysaccharide Conjugates

Carrier Polypeptide	ELISA Titer at Day			Op+ Titer at Day	ELISA titer to wild-type pneumolysin at Day
	0	42	59	59	59
Tetanus Toxoid	<50	287,000	170,000	28,000	<50
pNV103 #195 Phe-Val	<50	209,000	178,000	18,000	124,000
pNV207 #195 Phe-Ile	<50	175,000	149,000	31,000	111,000
pNV111 #148 Met-Lys	<50	137,000	127,000	10,500	84,000
pNV19	<50	275,000	241,000	29,000	124,000
Wild-type					
PBS	<50	<50	<50	<100	

* PnC 14 polysaccharide-specific antibody titer

+ Opsonophagocytic Titer

As can be seen from the data in Table 11, all of the modified pneumolysin conjugates elicited antibodies which had opsonophagocytic activity in the presence of complement. Mice immunized with all the above conjugates,

in addition to a strong IgG anti-PS response, mount a very strong IgG response against the pneumolysoid carriers and to the same extent as that raised against the conjugated wild-type pneumolysin.

5

Example 10

Preparation of tetravalent 6B/14/19F/23F pneumolysoid vaccines.

Preparation of conjugates.

10 The hydrolysis of polysaccharides was carried out as follows: type 6B PS was depolymerized with 0.1 N HCl at 60°C for 3 hrs and 45 min; type 14 was depolymerized with 0.1 N HCl at 60°C for 7 hrs ; type 19F was depolymerized with a 10 mM NaOAc buffer of pH 4.1 at 70°C for 2 hrs and 20 min; and type 23F was depolymerized
15 with 0.2M acetic acid solution at 100°C for 30 minutes.

Oxidized 6B PS was prepared as follows: the partially depolymerized PS (35 mg) was dissolved in 1750 ml DI water and treated with 250 ml of 10 mM NaIO₄ in the dark for 2 hrs at room temperature. The excess NaIO₄ was
20 destroyed with ethylene glycol, and after extensive dialysis the oxidized PS was lyophilized. Oxidized 14 PS was prepared as described above for type 6B. Oxidized 19F was prepared as follows: 50 mg of depolymerized PS was dissolved in 0.2 M sodium phosphate buffer pH 7.5 (5ml)
25 and treated with 41 ml of 100 mM NaIO₄ at 4°C overnight in the dark. Excess NaIO₄ destroyed with ethylene glycol and after extensive dialysis the oxidized 19F PS was lyophilized. Oxidized 23F was prepared as follows: 68 mg

of partially depolymerized PS was dissolved in 3.4 ml of 3 mM NaIO₄ solution at room temperature in the dark for 1 hour. The excess NaIO₄ was destroyed by the addition of ethylene glycol, and after extensive dialysis, the
5 oxidized PS was lyophilized to dryness.

The oxidized PSs were separately coupled to recombinant pneumolysoid mutant 207 in which amino acid Phe residue 195 was replaced by Ile. In brief, the oxidized PSs and the protein (5 mg/ml) in 0.2 M sodium
10 phosphate buffer were combined at a PS/protein ratio of about 2.5:1 by weight at room temperature and sodium cyanoborohydride (2 equivalents by weight) was then added. The conjugation mixtures were incubated at 37°C for 2 days. After reduction of the residual aldehydes of the
15 conjugated PS, with excess NaBH₄, the conjugates were purified from the reaction mixtures by passage through a column of Superdex 200 PG (Pharmacia) eluted with PBS containing 0.01% thimerosal as the preservative, except for the type 23 conjugate where the conjugate was loaded
20 onto a Q Sepharose Fast Flow column, and eluted with 10 mM Tris-HCl, pH 7.5 using a gradient of 0.5 M NaCl. Fractions corresponding to the conjugates were pooled and analyzed for protein and carbohydrate content as described in example 8 (see Table 12).

25

Table 12. Composition of pneumolysoid conjugates

Pneumococcal Serotype	Approx. MW of PS	Polypeptide (mg/ml)	PS (mg/ml)	% PS in conjugate
6B	41,000	0.24	0.14	37
14	41,000	0.13	0.08	38
19F	10,000	0.46	0.14	23
23F	90,000	0.44	0.06	12

Example 11

Immunization with pneumolysoid tetravalent vaccines.

Immunization of mice.

5 Six to 8 weeks old female outbred CD-1 mice
(Charles River, Raleigh) were immunized with monovalent
or tetravalent vaccines. Streptococcus pneumoniae
polysaccharides types 6B, 14, 19, and 23 were conjugated
to tetanus toxoid or pneumolysin mutant (0.5 µg PS/0.2 ml
10 to 2 µg PS/0.2 ml) in 1 mg/ml 1 alum. The vaccines were
administered subcutaneously, on days 0, 28, and 49, and
blood samples were collected on days 0, 14, 28, 38 and 59.
ELISA titers against polysaccharides and the carrier
protein were determined using HSA-PS conjugates and wild-
15 type pneumolysin (Figs. 8, 9 and 10). The opsonic
activity of the sera was determined in a phagocytic assay
using HL-60 cell line as described in Example 9 (Fig.
11).

Hemolysis assay.

The pneumolysin activity was assessed according to Paton et al. (1993) Infect. Immun. 40:548, with some modifications. In brief, on standard U-bottomed
5 microtiter plates, wild-type and mutant pneumolysin proteins were twofold serially diluted in TBS (15 mM Tris, 0.15 M NaCl, pH 7.5) plus 1 mM DTT as cofactor, in a final volume of 100 µl. One hundred microliters of 1% sheep erythrocyte suspension in TBS were added and the reaction
10 conducted at 37°C for 30 minutes. After spinning down the unlysed cells, the extent of the erythrocyte lysis was monitored in the supernatant at 405 nm using a microtiter plate reader. The end point of the assay was taken as the well in which 50% of erythrocytes were lysed, based on a
15 0.5% cell suspension lysed hypotonically.

Hemolysis inhibition assay of murine antisera.

Inhibition of the hemolytic activity was tested according to Paton et al. (1993) Infect. Immun. 40:548, with some variations. Before dilution, the mouse antisera
20 were treated twice with chloroform, to eliminate cholesterol. A twofold serial dilution of 50 µl of the mice antisera were performed and 50 µl of toxin stock solution at 4HU (hemolytic units) were added. The hemolytic activity of the toxins were assessed immediately
25 before the neutralization assay. After 15 min incubation at 37°C to allow serum antibody to bind to the pneumolysin, 100 µl sheep red blood (1% in TBS) (ICN, Costa Mesa, CA) was added in each well. The plates were incubated 30 min at 37°C and the unlysed cells were

pelleted by centrifugation. The extent of the erythrocyte lysis released in the supernatant was monitored at 405 nm using a microtiter plate reader. The antibody titers were taken as the highest dilutions of sera which gave complete inhibition of the hemolysis (Fig. 12).

Hemolysis inhibition assay by modified pneumolysin.

Modified pneumolysin polypeptides can be tested for their ability to inhibit the hemolytic activity of wild-type pneumolysin when pre-incubated with erythrocytes. A suspension of erythrocytes (3 ml) was incubated with 1 μ l (1 mg/ml) of each of the modified pneumolysin polypeptides for 10 min and the suspension added to wells of a microtiter plate containing serial dilutions of wild-type pneumolysin. The plate was incubated at 37 °C for 30 min and the hemolytic titer compared with a control incubation performed with normal erythrocytes. The selected mutants exert variable degrees of inhibition of the wild type hemolytic activity upon pre-incubation with erythrocytes (Fig. 13), suggesting that these mutants are capable of competing with the wild type for the binding site, but are unable to insert into membranes to form lytic channels. The mutants pNV103 and pNV207 represent the most effective inhibitors, followed by pNV111. The mutant pNV211 apparently does not exhibit such inhibition properties. Additional corroboration of the structural integrity and identity of the PLYD mutants is that most of their antigenicity is retained when compared to native PLY as shown in Figure 14.

Circular dichroism (CD) spectroscopy.

The secondary and tertiary structures of the free wild type and mutant pneumolysin and the respective conjugate were evaluated by circular dichroism (CD) spectroscopy in the far UV (180 to 250 nm) and near UV (250 to 350 nm) regions, respectively. Concentrated stock solutions of protein were dialyzed exhaustively against a buffer system comprised of 10 mM NaPO₄ (pH 8.0). Spectra of samples containing 1.0 mg/ml protein were recorded at 0.1 nm wavelength intervals on a JASCO Model 710 circular dichroism spectropolarimeter (JASCO, Easton, MD) employing a scan speed of 5 nm/min and average response time of 1 s. A minimum of four consecutive scans were accumulated and the average spectra stored. The temperature of the samples was maintained at 25 °C through the use of water-jacketed 0.01 cm and 1.0 cm pathlength cells in the far and near UV, respectively.

Fluorescence spectroscopy.

Fluorescence measurements were performed on an SLM AMINCO-Bowman 8100 Series 2 spectrofluorometer. Fluorescence spectra of samples containing 100 µg/ml protein in 10 mM NaPO₄ (pH 7.5) were recorded over the range of 300 to 500 nm employing an excitation wavelength of 290 nm and slit widths of 2 nm. Temperature stability was maintained through use of a water-jacketed 1.0 cm quartz cuvette thermostatted at 25°C.

A comparison of the fluorescence spectra of wild type pneumolysin and selected mutants has been performed under experimental conditions in which these proteins

adopt a native folded conformation. As evidenced in Fig. 15, the fluorescence spectra of all the proteins are characterized by a maximum emission intensity at ~345 nm, with somewhat higher amplitudes observed for the mutant proteins when compared to the wild type. Overall, the results indicate that all the proteins are in a native conformation, which is characterized by a significant number of Trp residues exposed to solvent. These results have been observed previously for perfringolysin, and are consistent with the presence of a Trp-rich cell-binding domain in the C-terminus of these cytolysins.

Basic structural and immunological features of pneumolysin (PLY), pneumolysoid (PLYD) and CPS-PLYD conjugates as assessed by circular dichroism.

PLY overexpressed in *E. coli* and refolded from inclusion bodies exhibits a typical far UV CD spectrum characteristic of a high content of β -sheets with a minimum observed at ~ 215 nm (Minetti et al. *Biophys. J.*, 1998, 74, A233) which does not significantly change in the single point mutation PLYD. Likewise, chemical conjugation of either PLY or PLYD with PnCPS does not affect the overall secondary structure of the proteins (Figure 16A). The near UV CD spectrum (Figure 16B) which derives from the relative asymmetry of tyrosyl and tryptophanyl residues in the protein has also been assessed in the free versus conjugate protein and reveals a highly ordered structure resembling the wild type free protein. The conjugate, however exhibits minor changes in the near UV CD profile as a result from the presence of

the polysaccharide on the surface of these complexes, interfering particularly with the specific Tyr signal (i.e., negative ellipticity with a minimum centered at ~ 280 nm), reduced in the respective conjugate. Additional
5 corroboration of the structural integrity and identity of the PLYD mutants is that most of their antigenicity is retained when compared to native PLY as shown in Figure 14.

Spectroscopic methods represent a powerful tool
10 in the evaluation of the integrity of proteins. In the particular case of conjugate vaccines which employ proteins as carriers, these methods, in conjunction with functional and immunological techniques may facilitate monitoring batch-to-batch variations as well as the
15 molecular basis for vaccine efficacy (Crane et al. *Eur. J. Biochem.* 1997, 246, 320-327; Jones et al. *Dev. Biol. Stand.* 1996, 87, 143-151). The mutations render the protein atoxic, but it retains the ability to refold to a native-like structure, indistinguishable from the parent
20 molecule. The nearly superimposable far UV CD spectra of the free mutant protein (i.e., pNV207) and the corresponding Pn 14 conjugate, as seen by both amplitude and crossover points, are indications that the secondary structure of the protein within this macromolecular
25 complex remains intact. These results contrast with previous studies conducted with other polysaccharide-protein conjugates in which light variations in the secondary structure were noticeable, following conjugation (Crane et al. *Eur. J. Biochem.* 1997, 246, 320-327).

The tyrosyl residues in the vicinity of the conjugation sites may be perturbed by the presence of the polysaccharide as indicated by the differences observed in the near UV CD spectra in the region around 280 nm.

5 However, the tryptophanyl peak, characteristic at 290 nm, remains unaffected by the conjugation, another indication that the Tyr-containing regions are not affected by the reductive amination procedure.

Overall the spectroscopic in conjunction with
10 the serological results provide excellent evidence that PLYD-CPS conjugates represent suitable vaccine candidates for the prevention of pneumococcal diseases.

Immunogenicity time course studies.

An immunogenicity time course study for the
15 tetravalent PLYD-PnCPS was carried out and is shown in Figure 17A. The animals received three injections at days 0, 28 and 49, and blood samples were obtained at days 0, 14, 28, 38, and 59. Each dose contained 0.5µg PnCPS of each type. The PnCPS-specific IgG response to each type
20 increased over time to peak just after the second injection (titers ranging between 20,000 and 50,000) and then reached a plateau. Significant booster effects were observed after the second injection.

In Figure 17B is shown the time course of the
25 PnCPS-specific IgG response of the tetravalent TT conjugate. Like for the PLYD combination vaccine, the animals were similarly immunized using the same schedule and same dose of vaccine. Again, the IgG response to each type polysaccharide increased after each injection with

similar magnitude (final titers between 50,000 and 200,000) except for type 23F which gave a significantly lower titer (ca: 5,000). Booster effects were also observed for each type after the second injection, except
5 for 23 which gave a much less pronounced effect.

For comparison with the above PLYD-PnCPS combination vaccine, the immunogenicity time course of the monovalent PLYD-PnCPS conjugates are shown in Figure 17C. The animals received the same doses of 0.5µg of PnCPS and
10 had the same immunization schedule as mentioned above. The time course of the IgG response to the PnCPS in those monovalent conjugates was almost identical to the one observed for the combination except for the type 23 PnCPS which gave rise to a less steeper time course curve, with
15 antibody titers an order of magnitude lower than those of the three other types.

The preclinical studies demonstrate that conjugates consisting of polysaccharides derived from four pneumococcal strains (6, 14, 19, and 23) and PLYD are
20 highly immunogenic in animals, and they elicited PnCPS-specific antibodies titers which compared well with those raised with a TT tetravalent conjugate. In addition, the PLYD tetravalent conjugate was able to generate high levels of PLY-specific IgG antibodies that neutralized
25 hemolytic activity of wild type PLY. In the light of a recently published report on the clear pathogenic role of PLY in the hearing loss and cochlear damage in a pneumococcal experimental meningitis model, it is clear that PLYD vaccine-induced antibodies will be a useful

adjunct to the capsular antibodies to ameliorate or even prevent the feared complications associated with otitis media (Winter et al. Infection and Immunity 1997, 65, 4411-4418).

We claim:

1. A modified pneumolysin polypeptide having attenuated hemolytic activity wherein said modified pneumolysin polypeptide is obtained by:
 - 5 a) randomly mutating a nucleic acid molecule encoding for wild-type pneumolysin to produce mutated nucleic acid molecules encoding modified pneumolysin polypeptides and expressing the mutated nucleic acid molecules in host cells;
 - 10 b) assaying the modified polypeptide expressed by the host cells for hemolytic activity;
 - 15 c) identifying the modified pneumolysin polypeptides having substantially similar molecular weight as native wild-type pneumolysin and which are refoldable.
2. A modified properly-refolded pneumolysin polypeptide having attenuated hemolytic activity comprising an amino acid sequence of type 14 pneumolysin wherein at least one amino acid in the region comprising amino acid residues 1 to 257 is substituted and wherein at least one of said amino acid substitutions results in attenuation of the hemolytic activity of the modified pneumolysin polypeptide.
- 25 3. The modified pneumolysin polypeptide of claim 2, wherein the hemolytic activity is less than 25% compared to wild-type pneumolysin.
4. A modified pneumolysin polypeptide according to claim 3, comprising at least one amino acid substitution in the amino acid sequence of Formula I at residue positions 61, 148, or 195 or the combination of substitutions at residue positions 33, 46, 83, 239 and 257
- 30

(Formula I)

	Met	Ala	Asn	Lys	Ala	Val	Asn	Asp	Phe	Ile	Leu	Ala
	1				5					10		
5	Met	Asn	Tyr	Asp	Lys	Lys	Lys	Leu	Leu	Thr	His	Gln
			15					20				
	Gly	Glu	Ser	Ile	Glu	Asn	Arg	Phe	Ile	Lys	Glu	Gly
	25					30					35	
	Asn	Gln	Leu	Pro	Asp	Glu	Phe	Val	Val	Ile	Glu	Arg
10				40					45			
	Lys	Lys	Arg	Ser	Leu	Ser	Thr	Asn	Thr	Ser	Asp	Ile
		50					55				60	
	Ser	Val	Thr	Ala	Thr	Asn	Asp	Ser	Arg	Leu	Tyr	Pro
				65						70		
15	Gly	Ala	Leu	Leu	Val	Val	Asp	Glu	Thr	Leu	Leu	Glu
			75					80				
	Asn	Asn	Pro	Thr	Leu	Leu	Ala	Val	Asp	Arg	Ala	Pro
	85					90					95	
	Met	Thr	Tyr	Ser	Ile	Asp	Leu	Pro	Gly	Leu	Ala	Ser
20				100					105			
	Ser	Asp	Ser	Phe	Leu	Gln	Val	Glu	Asp	Pro	Ser	Asn
		110					115				120	
	Ser	Ser	Val	Arg	Gly	Ala	Val	Asn	Asp	Leu	Leu	Ala
				125						130		
25	Lys	Trp	His	Gln	Asp	Tyr	Gly	Gln	Val	Asn	Asn	Val
			135				140					
	Pro	Ala	Arg	Met	Gln	Tyr	Glu	Lys	Ile	Thr	Ala	His
	145					150					155	
	Ser	Met	Glu	Gln	Leu	Lys	Val	Lys	Phe	Gly	Ser	Asp
30				160					165			
	Phe	Glu	Lys	Thr	Gly	Asn	Ser	Leu	Asp	Ile	Asp	Phe
		170					175				180	
	Asn	Ser	Val	His	Ser	Gly	Glu	Lys	Gln	Ile	Gln	Ile
				185						190		
35	Val	Asn	Phe	Lys	Gln	Ile	Tyr	Tyr	Thr	Val	Ser	Val
			195				200					
	Asp	Ala	Val	Lys	Asn	Pro	Gly	Asp	Val	Phe	Gln	Asp
	205					210					215	
	Thr	Val	Thr	Val	Glu	Asp	Leu	Lys	Gln	Arg	Gly	Ile
40				220					225			
	Ser	Ala	Glu	Arg	Pro	Leu	Val	Tyr	Ile	Ser	Ser	Val
		230					235				240	
	Ala	Tyr	Gly	Arg	Gln	Val	Tyr	Leu	Lys	Leu	Glu	Thr
				245						250		
45	Thr	Ser	Lys	Ser	Asp	Glu	Val	Glu	Ala	Ala	Phe	Glu
			255					260				
	Ala	Leu	Ile	Lys	Gly	Val	Lys	Val	Ala	Pro	Gln	Thr
	265					270					275	

	Glu	Trp	Lys	Gln	Ile	Leu	Asp	Asn	Thr	Glu	Val	Lys
				280					285			
	Ala	Val	Ile	Leu	Gly	Gly	Asp	Pro	Ser	Ser	Gly	Ala
	290						295					300
5	Arg	Val	Val	Thr	Gly	Lys	Val	Asp	Met	Val	Glu	Asp
					305					310		
	Leu	Ile	Gln	Glu	Gly	Ser	Arg	Phe	Thr	Ala	Asp	His
			315					320				
10	Pro	Gly	Leu	Pro	Ile	Ser	Tyr	Thr	Thr	Ser	Phe	Leu
	325					330					335	
	Arg	Asp	Asn	Val	Val	Ala	Thr	Phe	Gln	Asn	Ser	Thr
			340					345				
	Asp	Tyr	Val	Glu	Thr	Lys	Val	Thr	Ala	Tyr	Arg	Asn
	350					355						360
15	Gly	Asp	Leu	Leu	Leu	Asp	His	Ser	Gly	Ala	Tyr	Val
					365					370		
	Ala	Gln	Tyr	Tyr	Ile	Thr	Trp	Asn	Glu	Leu	Ser	Tyr
			375					380				
20	Asp	His	Gln	Gly	Lys	Glu	Val	Leu	Thr	Pro	Lys	Ala
	385					390					395	
	Trp	Asp	Arg	Asn	Gly	Gln	Asp	Leu	Thr	Ala	His	Phe
			400						405			
	Thr	Thr	Ser	Ile	Pro	Leu	Lys	Gly	Asn	Val	Arg	Asn
	410					415						420
25	Leu	Ser	Val	Lys	Ile	Arg	Glu	Cys	Thr	Gly	Leu	Ala
				425						430		
	Trp	Glu	Trp	Trp	Arg	Thr	Val	Tyr	Glu	Lys	Thr	Asp
			435					440				
30	Leu	Pro	Leu	Val	Arg	Lys	Arg	Thr	Ile	Ser	Ile	Trp
	445					450					455	
	Gly	Thr	Thr	Leu	Tyr	Pro	Gln	Val	Glu	Asp	Lys	Val
				460					465			
	Glu	Asn	Asp									
	470											

35 5. The modified pneumolysin according to claim 4,
 wherein a single amino acid substitution is made and
 the substituted amino acid is selected from the group
 consisting of proline or hydroxyproline for position
 61; lysine arginine or histidine for position 148 and
 40 leucine, glycine, alanine, isoleucine or valine for
 position 195.

6. The modified pneumolysin according to claim 3,
 wherein the substituted amino acids are selected from

the group consisting of serine, threonine, asparagine, glutamine, tyrosine or cystine for positions 33, 46 and 83; lysine arginine or histidine for position 239 and leucine, glycine, alanine, isoleucine or valine for position 255.

5

~~7.~~ Modified pneumolysin polypeptide pNVJ1.

~~8.~~ Modified pneumolysin polypeptide pNVJ20

~~9.~~ Modified pneumolysin polypeptide pNVJ22.

~~10.~~ Modified pneumolysin polypeptide pNVJ45.

10 ~~11.~~ Modified pneumolysin polypeptide pNVJ56.

~~12.~~ Modified pneumolysin polypeptide pNV103.

~~13.~~ Modified pneumolysin polypeptide pNV207

~~14.~~ Modified pneumolysin polypeptide pNV111.

~~15.~~ Modified pneumolysin polypeptide pNV211.

15 ~~16.~~ A recombinant nucleic acid molecule encoding a modified type 14 pneumolysin polypeptide wherein at least one amino acid in the region comprising amino acid residues 1 to 257 is substituted and wherein at least one of said amino acid substitutions results in
20 attenuation of the hemolytic activity of the modified pneumolysin polypeptide.

17. The recombinant nucleic acid molecule according to claim 16 comprising the following pneumolysin nucleic acid sequence:

25	ATGGCAAATA AAGCAGTAAA TGACTTTATA CTAGCTATGA	40
	ATTACGATAA AAAGAACTC TTGACCCATC AGGGAGAAAG	80

	TATTGAAAAT	CGTTTCATCA	AAGAGGGTAA	TCAGCTACCC	120
	GATGAGTTTG	TTGTTATCGA	AAGAAAGAAG	CGGAGCTTGT	160
	CGACAAATAC	AAGTGATATT	TCTGTAAACAG	CTACCAACGA	200
	CAGTCGCCTC	TATCCTGGAG	CACTTCTCGT	AGTGGATGAG	240
5	ACCTTGTTAG	AGAATAATCC	CACTCTTCTT	GCGGTCGATC	280
	GTGCTCCGAT	GACTTATAGT	ATTGATTTGC	CTGGTTTGGC	320
	AAGTAGCGAT	AGCTTTCTCC	AAGTGGAAGA	TCCCAGCAAT	360
	TCAAGTGTTT	GCGGAGCGGT	AAACGATTTG	TTGGCTAAGT	400
	GGCATCAAGA	TTATGGTCAG	GTCAATAATG	TCCCAGCTAG	440
10	AATGCAGTAT	GAAAAAATCA	CGGCTCACAG	CATGGAACAA	480
	CTCAAGGTCA	AGTTTGGTTC	TGACTTTGAA	AAGACAGGGA	520
	ATTCTCTTGA	TATTGATTTT	AACTCTGTCC	ATTCAGGCGA	560
	AAAGCAGATT	CAGATTGTTA	ATTTTAAGCA	GATTTATTAT	600
	ACAGTCAGCG	TAGACGCTGT	TAAAAATCCA	GGAGATGTGT	640
15	TTCAAGATAC	TGTAACGGTA	GAGGATTTAA	AACAGAGAGG	680
	AATTTCTGCA	GAGCGTCCTT	TGGTCTATAT	TTCGAGTGTT	720
	GCTTATGGGC	GCCAAGTCTA	TCTCAAGTTG	GAAACCACGA	760
	GTAAGAGTGA	TGAAGTAGAG	GCTGCTTTTG	AAGCTTTGAT	800
	AAAAGGAGTC	AAGGTAGCTC	CTCAGACAGA	GTGGAAGCAG	840
20	ATTTTGGACA	ATACAGAAGT	GAAGGCGGTT	ATTTTAGGGG	880
	GCGACCCAAG	TTCGGGTGCC	CGAGTTGTAA	CAGGCAAGGT	920
	GGATATGGTA	GAGGACTTGA	TTCAAGAAGG	CAGTCGCTTT	960
	ACAGCAGATC	ATCCAGGCTT	GCCGATTTCC	TATACAACTT	1000
	CTTTTTTACG	TGACAATGTA	GTTGCGACCT	TTCAAAATAG	1040
25	TACAGACTAT	GTTGAGACTA	AGGTTACAGC	TTACAGAAAC	1080
	GGAGATTTAC	TGCTGGATCA	TAGTGGTGCC	TATGTTGCCC	1120
	AATATTATAT	TACTTGGAAT	GAATTATCCT	ATGATCATCA	1160
	AGGTAAGGAA	GTCTTGACTC	CTAAGGCTTG	GGACAGAAAT	1200
	GGGCAGGATT	TAACGGCTCA	CTTTACCACT	AGTATTCCTT	1240
30	TAAAAGGGAA	TGTTTCGTAAT	CTCTCTGTCA	AAATTAGAGA	1280
	GTGTACCGGG	CTTGCTTGGG	AATGGTGGCG	TACGGTTTAT	1320
	GAAAAAACCG	ATTTGCCACT	AGTGCGTAAG	CGGACGATTT	1360
	CTATTTGGGG	AACAACCTCT	TATCCGCAGG	TAGAAGATAA	1400
	GGTAGAAAAT	GAC			1413

35 and wherein said nucleic acid sequence comprises one or more of the nucleotide substitutions selected from the group consisting of:

A-50→G, G-54→T, T-181→C, A-196→T and T-302→C;

40 A-122→G, A-514→G, T-583→A and A-764→G;

A-187→T, T-380→A, A-382→C and T-443→A;

T-98→C, T-137→C, T-248→C, T-717→A and A-770→G;

T-134→C, A-305→G, A-566→G and T-583→G;

T-583→G;

5

T-583→A;

T-443→A;

and

10

T-181→C.

18. The recombinant nucleic acid molecule of claim 16 as contained in a vector such as a plasmid, cosmid, bacteriophage or yeast artificial chromosome.

19. A microorganism comprising the nucleic acid molecule of claim 16.

15

20. The microorganism according to claim 19, wherein the microorganism is selected from the group consisting of bacteria, yeast, mammalian or insect cells.

21. The microorganism according to claim 20, wherein the microorganism is *E. coli*.

20

22. The modified pneumolysin polypeptide of claim 1, wherein the polypeptide is conjugated to a polysaccharide which elicits antibodies cross-reactive with a bacterial polysaccharide.

25

23. The modified pneumolysin conjugate of claim 22, wherein the polysaccharide is from a bacteria selected from the group consisting of a Haemophilus influenzae type b; meningococcal group A, B or C; group B streptococcus types Ia, Ib, II, III, V or

VIII and pneumococcal.

24. A vaccine comprising at least one pneumolysin polypeptide of claim 1 and a pharmaceutically acceptable carrier.
- 5 25. The vaccine according to claim 24, wherein the polypeptide is conjugated to a polysaccharide which elicits antibodies cross-reactive with a bacterial polysaccharide.
- 10 26. The vaccine according to claim 25, wherein the polysaccharide is derived from a bacteria selected from the group consisting of Haemophilus influenzae type b; meningococcus group A, B, or C; group A streptococcus or group B streptococcus serotypes Ia, Ib, II, III, V, or VIII; or one or more of serotypes 15 1-23 of *S. pneumoniae*.
27. A method for killing bacteria comprising contacting said bacteria with antibodies to an immunogenic molecule comprising the modified pneumolysin according to claim 1 in the presence of complement.
- 20 28. The method according to claim 27, wherein the immunogenic molecule is a polysaccharide-polypeptide conjugate wherein the polysaccharide is a bacterial capsular polysaccharide.
- 25 29. A method for immunization of mammals comprising administering the vaccine of claim 24 to said mammals.
30. A method for obtaining modified pneumolysin polypeptides having reduced hemolytic activity and

being suitable for eliciting an immunogenetic response which is cross-reactive with wild-type pneumolysin comprising the steps of:

- 5 a) randomly mutating a nucleic acid molecule encoding for wild-type pneumolysin to produce mutated nucleic acid molecules encoding modified pneumolysin polypeptides and expressing the mutated nucleic acid molecules in host cells;
- 10 b) assaying the modified polypeptide expressed by the host cells for hemolytic activity;
- c) identifying the modified pneumolysin polypeptides having substantially similar molecular weight as native wild-type
- 15 pneumolysin and which are refoldable.

ABSTRACT:

This invention relates to modified pneumolysin polypeptides that retain the immunogenic nature of pneumolysin but have reduced or undetectable hemolytic activity compared to native pneumolysin. The invention also provides a method for generating novel pneumolysin variants with these desired characteristic properties. The invention also provides immunogenic compositions useful as pharmaceutical compositions including vaccines in which non-toxic, modified pneumolysin is used to stimulate protective immunity against *Streptococcus pneumoniae*. The vaccines may be compositions in which the modified pneumolysin is conjugated to bacterial polysaccharides or may be carried on an attenuated viral vector. In addition, the invention also provides a method of using the non-toxic, modified pneumolysin toxoid in order to stimulate antibodies against *Streptococcus pneumoniae* in a treated individual which are then isolated and transferred to a second individual, thereby conferring protection against *Streptococcus pneumoniae* in the second individual.

1/23

ATGGCAAATA	AAGCAGTAAA	TGACTTTTATA	CTAGCTATGA	40
ATTACGATAA	AAAGAAACTC	TTGACCCATC	AGGGAGAAAG	80
TATTGAAAAT	CGTTTCATCA	AAGAGGGTAA	TCAGCTACCC	120
GATGAGTTTG	TTGTTATCGA	AAGAAAGAAG	CGGAGCTTGT	160
CGACAAATAC	AAGTGATATT	TCTGTAACAG	CTACCAACGA	200
CAGTCGCCTC	TATCCTGGAG	CACTTCTCGT	AGTGGATGAG	240
ACCTTGTTAG	AGAATAATCC	CACTCTTCTT	GCGGTCGATC	280
GTGCTCCGAT	GACTTATAGT	ATTGATTTGC	CTGGTTTGGC	320
AAGTAGCGAT	AGCTTTCTCC	AAGTGGAAGA	TCCCAGCAAT	360
TCAAGTGTTT	GCGGAGCGGT	AAACGATTTG	TTGGCTAAGT	400
GGCATCAAGA	TTATGGTCAG	GTCAATAATG	TCCCAGCTAG	440
AATGCAGTAT	GAAAAAATCA	CGGCTCACAG	CATGGAACAA	480
CTCAAGGTCA	AGTTTGGTTC	TGACTTTTGAA	AAGACAGGGA	520
ATTCTCTTGA	TATTGATTTT	AACTCTGTCC	ATTCAGGCGA	560
AAAGCAGATT	CAGATTGTTA	ATTTTAAGCA	GATTTATTAT	600
ACAGTCAGCG	TAGACGCTGT	TAAAAATCCA	GGAGATGTGT	640
TTCAAGATAC	TGTAACGGTA	GAGGATTTAA	AACAGAGAGG	680
AATTTCTGCA	GAGCGTCCTT	TGGTCTATAT	TTCGAGTGTT	720
GCTTATGGGC	GCCAAGTCTA	TCTCAAGTTG	GAAACCACGA	760
GTAAGAGTGA	TGAAGTAGAG	GCTGCTTTTG	AAGCTTTGAT	800
AAAAGGAGTC	AAGGTAGCTC	CTCAGACAGA	GTGGAAGCAG	840
ATTTTGGACA	ATACAGAAGT	GAAGGCGGTT	ATTTTAGGGG	880
GCGACCCAAG	TTCGGGTGCC	CGAGTTGTAA	CAGGCAAGGT	920
GGATATGGTA	GAGGACTTGA	TTCAAGAAGG	CAGTCGCTTT	960

FIG. 1

2/23

ACAGCAGATC ATCCAGGCTT GCCGATTTCC TATACAACTT	1000
CTTTTTTACG TGACAATGTA GTTGCGACCT TTCAAAATAG	1040
TACAGACTAT GTTGAGACTA AGGTTACAGC TTACAGAAAC	1080
GGAGATTTAC TGCTGGATCA TAGTGGTGCC TATGTTGCCC	1120
AATATTATAT TACTTGGAAT GAATTATCCT ATGATCATCA	1160
AGGTAAGGAA GTCTTGACTC CTAAGGCTTG GGACAGAAAT	1200
GGGCAGGATT TAACGGCTCA CTTTACCACT AGTATTCCTT	1240
TAAAAGGGAA TGTTTCGTAAT CTCTCTGTCA AAATTAGAGA	1280
GTGTACCGGG CTTGCTTGGG AATGGTGGCG TACGGTTTAT	1320
GAAAAAACCG ATTTGCCACT AGTGCGTAAG CGGACGATTT	1360
CTATTTGGGG AACAACTCTC TATCCGCAGG TAGAAGATAA	1400
GGTAGAAAAT GAC	1413

FIG. 1

3/23

ATGGCAAATA AAGCAGTAAA TGACTTTATA CTAGCTATGA	40
ATTACGATAN ₅₀ AAAN ₅₄ AAACTC TTGACCCATC AGGGAGAAAG	80
TATTGAAAAT CGTTTCAN ₉₈ CA AAGAGGGTAA TCAGCTACCC	120
GN ₁₂₂ TGAGTTTG TTGN ₁₃₄ TAN ₁₃₇ CGA AAGAAAGAAG CGGAGCTTGT	160
CGACAAATAC AAGTGATATT N ₁₈₁ CTGTAN ₁₈₇ CAG CTACCN ₁₉₆ ACGA	200
CAGTCGCCTC TATCCTGGAG CACTTCTCGT AGTGGATGAG	240
ACCTTGTN ₂₄₈ AG AGAATAATCC CACTCTTCTT GCGGTN ₂₇₆ GATC	280
GTGCTCCGAT GACTTATAGT AN ₃₀₂ TGN ₃₀₅ TTTGC CTGGTTTGGC	320
AAGTAGCGAT AGCTTTCTCC AAGTGGAAGA N ₃₅₁ CCCAGCAAT	360
TCAAGTGTTT GCGGAGCGGN ₃₈₀ AN ₃₈₂ ACGATTTG TTGGCTAAGT	400
GGCATCAAGA TTATGGTCAG GTCAATAATG TCCCAGCTAG	440
AAN ₄₄₃ GCAGTAT GAAAAAATN ₄₅₉ A CGGCTCACAG CATGGAACAA	480
CTCAAGGTCA AGTTTGGTTC TGACTTTGAA AAGN ₅₁₄ CAGGGA	520
ATTCTCTTGA TATTGATTTT AACTCTGTCC ATTCAAGN ₅₅₈ GA	560
AAAGCN ₅₆₆ GATT CAGATTGTTA ATN ₅₈₃ TTAAGCA GATTTATTAT	600
ACAGTCAGCG TAGACGCTGT TAAAAATCCA GGAGATGTGT	640
TTCAAGATAC TGTAACGGTA GAGGATTTAA AACAGAGAGG	680
AATTTCTGCA GAGCGTCCTT TGGTCTATAT TTCGAGN ₇₁₇ GTT	720
GCTTATGGGC GCCAAGCTA TCTCAAGTTG GAAACCACGA	760
GTAN ₇₆₄ GAGTGN ₇₇₀ TGAAGTAGAG GCTGCTTTTG AAGCTTTGAT	800
AAAAGGAGTC AAGGTAGCTC CTCAGACAGA GTGGAAGCAG	840
ATTTTGGACA ATACAGAAGT GAAGGCGGTT ATTTTAGGGG	880
GCGACCCAAG TTCGGGTGCC CGAGTTGTAA CAGGCAAGGT	920
GGATATGGTA GAGGACTTGA TTCAAGAAGG CAGTCGCTTT	960
ACAGCAGATC ATCCAGGCTT GCCGATTTCC TATACAACTT	1000

FIG. 2

4/23

CTTTTTTACG TGACAATGTA GTTGCGACCT TTCAAAAN ₁₀₃₈ AG	1040
TACAGACTAT GTTGAGACTA AGGTTACAGC TTACAGAAAC	1080
GGAGATTTAC TGCTGGATCA TAGTGGTGCC TATGTTGCCC	1120
AATATTATAT TACTTGGN ₁₁₃₈ AT GAATTATCCT ATGATCATCA	1160
AGGTAAGGAA GTCTTGACTC CTAAGGCTTG GGACAGAAAT	1200
GGGCAGGATT TN ₁₂₁₂ ACGGCTCA CTTTACCACT AGTATTCCTT	1240
TAAAAGGGAA TGTTCTGTAAT CTCTCTGTCA AAATTAGAGA	1280
GTGTACCGGG CTTGCN ₁₂₉₆ TGGG AATGGTGGCG TACGGTTTAT	1320
GAAAAAACCG ATTTGCCACT AGTGCGTAAG CGGACGATTT	1360
CTATTTGGGG AACAACTCTC TATCCN ₁₃₈₆ CAGG TAGAN ₁₃₉₅ GATAA	1400
GGTAGAAAAT GAC	1413

FIG. 2

5/23

Met	Ala	Asn	Lys	Ala	Val	Asn	Asp	Phe	Ile	Leu	Ala
1				5					10		
Met	Asn	Tyr	Asp	Lys	Lys	Lys	Leu	Leu	Thr	His	Gln
		15					20				
Gly	Glu	Ser	Ile	Glu	Asn	Arg	Phe	Ile	Lys	Glu	Gly
25				30						35	
Asn	Gln	Leu	Pro	Asp	Glu	Phe	Val	Val	Ile	Glu	Arg
			40					45			
Lys	Lys	Arg	Ser	Leu	Ser	Thr	Asn	Thr	Ser	Asp	Ile
	50					55					60
Ser	Val	Thr	Ala	Thr	Asn	Asp	Ser	Arg	Leu	Tyr	Pro
				65					70		
Gly	Ala	Leu	Leu	Val	Val	Asp	Glu	Thr	Leu	Leu	Glu
		75					80				
Asn	Asn	Pro	Thr	Leu	Leu	Ala	Val	Asp	Arg	Ala	Pro
85				90						95	
Met	Thr	Tyr	Ser	Ile	Asp	Leu	Pro	Gly	Leu	Ala	Ser
			100					105			
Ser	Asp	Ser	Phe	Leu	Gln	Val	Glu	Asp	Pro	Ser	Asn
	110				115						120
Ser	Ser	Val	Arg	Gly	Ala	Val	Asn	Asp	Leu	Leu	Ala
				125					130		
Lys	Trp	His	Gln	Asp	Tyr	Gly	Gln	Val	Asn	Asn	Val
		135				140					
Pro	Ala	Arg	Met	Gln	Tyr	Glu	Lys	Ile	Thr	Ala	His
145				150						155	
Ser	Met	Glu	Gln	Leu	Lys	Val	Lys	Phe	Gly	Ser	Asp
			160					165			
Phe	Glu	Lys	Thr	Gly	Asn	Ser	Leu	Asp	Ile	Asp	Phe
	170				175						180
Asn	Ser	Val	His	Ser	Gly	Glu	Lys	Gln	Ile	Gln	Ile
				185					190		
Val	Asn	Phe	Lys	Gln	Ile	Tyr	Tyr	Thr	Val	Ser	Val
		195				200					
Asp	Ala	Val	Lys	Asn	Pro	Gly	Asp	Val	Phe	Gln	Asp
205				210						215	
Thr	Val	Thr	Val	Glu	Asp	Leu	Lys	Gln	Arg	Gly	Ile
			220					225			
Ser	Ala	Glu	Arg	Pro	Leu	Val	Tyr	Ile	Ser	Ser	Val
	230				235						240
Ala	Tyr	Gly	Arg	Gln	Val	Tyr	Leu	Lys	Leu	Glu	Thr
				245					250		
Thr	Ser	Lys	Ser	Asp	Glu	Val	Glu	Ala	Ala	Phe	Glu
		255					260				
Ala	Leu	Ile	Lys	Gly	Val	Lys	Val	Ala	Pro	Gln	Thr
265				270						275	
Glu	Trp	Lys	Gln	Ile	Leu	Asp	Asn	Thr	Glu	Val	Lys
			280					285			

FIG. 3

6/23

Ala	Val	Ile	Leu	Gly	Gly	Asp	Pro	Ser	Ser	Gly	Ala
290						295					300
Arg	Val	Val	Thr	Gly	Lys	Val	Asp	Met	Val	Glu	Asp
				305					310		
Leu	Ile	Gln	Glu	Gly	Ser	Arg	Phe	Thr	Ala	Asp	His
		315					320				
Pro	Gly	Leu	Pro	Ile	Ser	Tyr	Thr	Thr	Ser	Phe	Leu
325					330					335	
Arg	Asp	Asn	Val	Val	Ala	Thr	Phe	Gln	Asn	Ser	Thr
			340					345			
Asp	Tyr	Val	Glu	Thr	Lys	Val	Thr	Ala	Tyr	Arg	Asn
	350					355					360
Gly	Asp	Leu	Leu	Leu	Asp	His	Ser	Gly	Ala	Tyr	Val
				365					370		
Ala	Gln	Tyr	Tyr	Ile	Thr	Trp	Asn	Glu	Leu	Ser	Tyr
		375					380				
Asp	His	Gln	Gly	Lys	Glu	Val	Leu	Thr	Pro	Lys	Ala
385					390					395	
Trp	Asp	Arg	Asn	Gly	Gln	Asp	Leu	Thr	Ala	His	Phe
			400					405			
Thr	Thr	Ser	Ile	Pro	Leu	Lys	Gly	Asn	Val	Arg	Asn
	410					415					420
Leu	Ser	Val	Lys	Ile	Arg	Glu	Cys	Thr	Gly	Leu	Ala
				425					430		
Trp	Glu	Trp	Trp	Arg	Thr	Val	Tyr	Glu	Lys	Thr	Asp
		435					440				
Leu	Pro	Leu	Val	Arg	Lys	Arg	Thr	Ile	Ser	Ile	Trp
445					450					455	
Gly	Thr	Thr	Leu	Tyr	Pro	Gln	Val	Glu	Asp	Lys	Val
			460					465			
Glu	Asn	Asp									
	470										

FIG. 3

7/23

Met Ala Asn Lys Ala Val Asn Asp Phe Ile Leu Ala
1 5 10
Met Asn Tyr Asp Xaa Xaa Lys Leu Leu Thr His Gln
15 20
Gly Glu Ser Ile Glu Asn Arg Phe Xaa Lys Glu Gly
25 30 35
Asn Gln Leu Pro Xaa Glu Phe Val Xaa Xaa Glu Arg
40 45
Lys Lys Arg Ser Leu Ser Thr Asn Thr Ser Asp Ile
50 55 60
Xaa Val Xaa Ala Thr Xaa Asp Ser Arg Leu Tyr Pro
65 70
Gly Ala Leu Leu Val Val Asp Glu Thr Xaa Leu Glu
75 80
Asn Asn Pro Thr Leu Leu Ala Val Asp Arg Ala Pro
85 90 95
Met Thr Tyr Ser Xaa Xaa Leu Pro Gly Leu Ala Ser
100 105
Ser Asp Ser Phe Leu Gln Val Glu Asp Pro Ser Asn
110 115 120
Ser Ser Val Arg Gly Ala Xaa Xaa Asp Leu Leu Ala
125 130
Lys Trp His Gln Asp Tyr Gly Gln Val Asn Asn Val
135 140
Pro Ala Arg Xaa Gln Tyr Glu Lys Xaa Thr Ala His
145 150 155
Ser Met Glu Gln Leu Lys Val Lys Phe Gly Ser Asp
160 165
Phe Glu Lys Xaa Gly Asn Ser Leu Asp Ile Asp Phe
170 175 180
Asn Ser Val His Ser Gly Glu Lys Xaa Ile Gln Ile
185 190
Val Asn Xaa Lys Gln Ile Tyr Tyr Thr Val Ser Val
195 200
Asp Ala Val Lys Asn Pro Gly Asp Val Phe Gln Asp
205 210 215
Thr Val Thr Val Glu Asp Leu Lys Gln Arg Gly Ile
220 225
Ser Ala Glu Arg Pro Leu Val Tyr Ile Ser Xaa Val
230 235 240
Ala Tyr Xaa Arg Gln Val Tyr Leu Lys Leu Glu Thr
245 250
Thr Ser Xaa Ser Xaa Glu Val Glu Ala Ala Phe Glu
255 260
Ala Leu Ile Lys Gly Val Lys Val Ala Pro Gln Thr
265 270 275
Glu Trp Lys Gln Ile Leu Asp Asn Thr Xaa Val Lys
280 285

FIG. 4

8/23

Ala	Val	Ile	Leu	Gly	Gly	Asp	Pro	Ser	Ser	Gly	Ala
290						295					300
Arg	Val	Val	Thr	Gly	Lys	Val	Asp	Met	Val	Glu	Asp
				305						310	
Leu	Ile	Gln	Glu	Gly	Ser	Arg	Phe	Thr	Ala	Asp	His
		315					320				
Pro	Gly	Leu	Pro	Ile	Ser	Tyr	Thr	Thr	Ser	Phe	Leu
325					330					335	
Arg	Asp	Asn	Val	Val	Ala	Thr	Phe	Gln	Asn	Ser	Thr
			340								
Asp	Tyr	Val	Glu	Thr	Lys	Val	Thr	Ala	Tyr	Arg	Asn
350						355					360
Gly	Asp	Leu	Leu	Leu	Asp	His	Ser	Gly	Ala	Tyr	Val
				365							
Ala	Gln	Tyr	Tyr	Ile	Thr	Trp	Xaa	Glu	Leu	Ser	Tyr
			375				380				
Asp	His	Gln	Gly	Lys	Glu	Val	Leu	Thr	Pro	Lys	Ala
385					390					395	
Trp	Asp	Arg	Asn	Gly	Gln	Asp	Leu	Thr	Ala	His	Phe
			400								
Thr	Thr	Ser	Ile	Pro	Leu	Lys	Gly	Asn	Val	Arg	Asn
						415					420
Leu	Ser	Val	Lys	Ile	Arg	Glu	Cys	Thr	Gly	Leu	Ala
				425							
Trp	Glu	Trp	Trp	Arg	Thr	Val	Tyr	Glu	Lys	Thr	Asp
		435					440				
Leu	Xaa	Leu	Val	Arg	Lys	Arg	Thr	Ile	Ser	Ile	Trp
445					450					455	
Gly	Thr	Thr	Leu	Tyr	Pro	Gln	Val	Glu	Asp	Lys	Val
			460								
Glu	Asn	Asp									
			470								

FIG. 4

9/23




Fig. 5

10/23





Fig. 6

11/23





Fig. 7

12/23

FIG. 8




**Polysaccharide Dose Response for Pneumococcal Pneumolysin
Conjugates in Mice after 2 Injections: Polysaccharide-Specific IgG**

333 333 333 333 333 333 333 333 333 333

13/23

FIG. 9

Polysaccharide-Specific IgG for Tetraivalent Pneumococcal Conjugates in Mice after 2 Injections: Pneumolysin versus Tetanus Toxoid Carriers




■ 0.5 µg PS - Pneumolysin ■ 0.5 µg PS - Tetanus Toxoid
▨ 2.0 µg PS - Pneumolysin ▨ 2.0 µg PS - Tetanus Toxoid

Pneumolysin-Specific IgG Elicited by Monovalent & Tetravalent Pneumococcal Polysaccharide-Pneumolysin Conjugates in Mice after 2 Injections


14/23

FIG. 10




15/23

FIG. 11



16/23

FIG. 12



■ 0.5 μg PS ■ 2.0 μg PS

17/23




FIG 13

18/23




Fig 14.

19/23





FIG 15

20/23

$(\theta) (10^2 \text{ deg} \cdot \text{cm}^2 \cdot \text{dmol}^{-1})$



Wavelength (nm)

FIG 16

CD Spectra of Mutant Pneumolysin (Free Protein and Conjugate)

2025 RELEASE UNDER E.O. 14176

Tetavalent Pneumococcal Pneumolysoid Conjugate Vaccine in Mice: Polysaccharide-Specific IgG Response over Time




Fig 17A



NORTH AMERICAN VACCINE, INC.

TetraValent Pneumococcal TT Conjugate Vaccine (2nd) in Mice: Polysaccharide-Specific IgG Response over Time





Fig 17B



NORTH AMERICAN VACCINE, INC.

Monovalent Pneumococcal Pneumolysoid Conjugate Vaccines in Mice: Polysaccharide-Specific IgG Response over Time



COMBINED DECLARATION AND POWER OF ATTORNEY FOR
ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL
DIVISIONAL, CONTINUATION OR CONTINUATION-IN-PART APPLICATION

As a below name inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

MODIFIED IMMUNOGENIC PNEUMOLYSIN COMPOSITIONS AS VACCINES
the specification of which

a. ☒ is attached hereto

b. ☐ was filed on _____ as application Serial No. _____ and was amended on _____ (if applicable).

PCT FILED APPLICATION ENTERING NATIONAL STATE

c. ☐ was described and claimed in International Application No. _____ filed on _____ and as amended on _____ (if any).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby specify the following as the correspondence address to which all communications about this application are to be directed:

SEND CORRESPONDENCE TO: MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, N.Y. 10154

DIRECT TELEPHONE CALLS TO: KENNETH H. SONNENFELD
(212) 758-4800

☐ I hereby claim foreign priority benefits under Title 35, United States Code § 119(a)-(d) or under § 365(b) of any foreign application(s) for patent or inventor's certificate or under § 365(a) of any PCT international application(s) designating at least one country other than the U.S. listed below and also have identified below such foreign application(s) for patent or inventor's certificate or such PCT international application(s) filed by me on the same subject matter having a filing date within twelve (12) months before that of the application on which priority is claimed:

☐ The attached 35 U.S.C. § 119 claim for priority for the application(s) listed below forms a part of this declaration.

<u>Country/PCT</u>	<u>Application Number</u>	<u>Date of filing (day, month, yr)</u>	<u>Date of Issue (day, month, yr)</u>	<u>Priority Claimed</u>
				[] YES [] NO
				[] YES [] NO
				[] YES [] NO

[X] I hereby claim the benefit under 35 U.S.C. § 119(e) of any U.S. provisional application(s) listed below.

<u>Provisional Application No.</u>	<u>Date of Filing (day, month, yr)</u>
60/053,306	July 21, 1997
60/073,456	February 2, 1998

ADDITIONAL STATEMENTS FOR DIVISIONAL, CONTINUATION OR CONTINUATION-IN-PART
OR PCT INTERNATIONAL APPLICATION(S) (DESIGNATING THE U.S.)

I hereby claim the benefit under Title 35, United States Code § 120 of any United States application(s) or under § 365(c) of any PCT international application(s) designating the U.S. listed below.

<u>US/PCT Application Serial No.</u>	<u>Filing Date</u>	<u>Status (patented, pending, abandoned)/ U.S. application no. assigned (For PCT)</u>

[] In this continuation-in-part application, insofar as the subject matter of any of the claims of this application is not disclosed in the above listed prior United States or PCT international application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or Imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following attorneys and/or agents with full power of substitution and revocation, to prosecute this application, to receive the patent, and to transact all business in the Patent and Trademark Office connected therewith: John A. Diaz (Reg. No. 19,550), John C. Vassil (Reg. No. 19,098), Alfred P. Ewert (Reg. No. 19,887), David H. Pfeffer, P.C. (Reg. No. 19,825), Harry C. Marcus (Reg. No. 22,390), Robert E. Paulson (Reg. No. 21,046), Stephen R. Smith (Reg. No. 22,615), Kurt E. Richter (Reg. No. 24,052), J. Robert Dailey (Reg. No. 27,434), Eugene Moroz (Reg. No. 25,237), John F. Sweeney (Reg. No. 27,471), Arnold I. Rady (Reg. No. 26,601), Christopher A. Hughes (Reg. No. 26,914), William S. Feiler (Reg. No. 26,728), Joseph A.

Calvaruso (Reg. No. 28,287), James W. Gould (Reg. No. 28,859), Richard C. Komson (Reg. No. 27,913), Israel Blum (Reg. No. 26,710), Bartholomew Verdirame (Reg. No. 28,483), Maria C.H. Lin (reg. No. 29,323), Joseph A. DeGirolamo (Reg. No. 28,595), Michael A. Nicodema (Reg. No. 33,199), Michael P. Dougherty (Reg. No. 32,730), Seth J. Atlas (Reg. No. 32,454), Andrew M. Riddles (Reg. No. 31,657), Bruce D. DeRenzi (Reg. No. 33,676), Michael M. Murray (Reg. No. 32,537) and Mark J. Abate (Reg. No. 32,527) of Morgan & Finnegan, L.L.P. whose address is: 345 Park Avenue, New York, New York, 10154; and Edward A. Pennington (Reg. No. 32,588) of Morgan & Finnegan, L.L.P., whose address is 1775 Eye Street, Suite 400, Washington, D.C. 20006.

☐ I hereby authorize the U.S. attorneys and/or agents named hereinabove to accept and follow instructions from _____ as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and/or agents and me. In the event of a change in the person(s) from whom instructions may be taken I will so notify the U.S. attorneys and/or agents hereinabove.

Full name of sole or first inventor CONCEICAO MINETTI

Inventor's signature* _____ date _____

Residence 3904 Isbell Street, Silver Spring, MD 20306

Citizenship Brazil

Post Office Address 3904 Isbell Street, Silver Spring, MD 20306

Full name of second joint inventor FRANCIS MICHON

Inventor's signature* _____ Date _____

Residence 4401 Rosedale Avenue, Bethesda, MD 20814

Citizenship Canada

Post Office Address 4401 Rosedale, Avenue, Bethesda, MD 20814

☒ ATTACHED IS ADDED PAGE TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR SIGNATURE BY THIRD AND SUBSEQUENT INVENTORS FORM.

* Before signing this declaration, each person signing must:

1. Review the declaration and verify the correctness of all information therein; and
2. Review the specification and the claims, including any amendments made to the claims.

After the declaration is signed, the specification and claims are not to be altered.

ADDED PAGE TO COMBINED DECLARATION
AND POWER OF ATTORNEY FOR
SIGNATURE BY THIRD AND SUBSEQUENT INVENTOR

Full name of third joint inventor, if any JEFFREY K. PULLEN

Inventor's signature* _____
date

Residence 6928 Garland Lane, Columbia, MD 21045

Citizenship United States of America

Post Office Address 6928 Garland Lane, Columbia, MD 21045

Full name of fourth joint inventor, if any MARYELLEN POLDVINO-BODNAR

Inventor's signature* _____
date

Residence 621 Rolling Dale Road, Annapolis, MD 21401

Citizenship United States of America

Post Office Address 621 Rolling Dale Road, Annapolis, MD 21401

Full name of fifth joint inventor, if any SHU-MEI LIANG

Inventor's signature* _____
date

Residence 6627 River Road, Bethesda, MD 20817

Citizenship United States of America

Post Office Address 6627 River Road, Bethesda, MD 20817

* Before signing this declaration, each person signing must:

1. Review the declaration and verify the correctness of all information therein; and
2. Review the specification and the claims, including any amendments made to the claims.

After the declaration is signed, the specification and claims are not to be altered.

ADDED PAGE TO COMBINED DECLARATION
AND POWER OF ATTORNEY FOR
SIGNATURE BY THIRD AND SUBSEQUENT INVENTOR

Full name of sixth joint inventor, if any JOSEPH Y. TAI

Inventor's signature* _____
date

Residence 1370 Cinnamon Drive, Port Washington, PA 19034

Citizenship United States of America

Post Office Address 1370 Cinnamon Drive, Port Washington, PA 19034

Full name of seventh joint inventor, if any _____

Inventor's signature* _____
date

Residence _____

Citizenship _____

Post Office Address _____

Full name of eighth joint inventor, if any _____

Inventor's signature* _____
date

Residence _____

Citizenship _____

Post Office Address _____

* Before signing this declaration, each person signing must:

1. Review the declaration and verify the correctness of all information therein; and
2. Review the specification and the claims, including any amendments made to the claims.

After the declaration is signed, the specification and claims are not to be altered.

To the inventor(s):

The following are cited in or pertinent to the declaration attached to the accompanying application:

Title 37, Code of Federal Regulation, § 1.56

Duty to disclose information material to patentability.

(a) A patent by its very nature is affect with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in patent was cited by the Office or submitted to the Office in the manner prescribed by §§1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) prior art cited in search reports of a foreign patent office in a counterpart application,
- and
- (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

Title 35, U.S. Code § 101

Inventions patentable

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Title 35 U.S. Code § 102

Conditions for patentability; novelty and loss of right to patent

A person shall be entitled to a patent unless –

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent,
- (b) the invention was patented or described in a printed publication in this or foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States, or
- (c) he has abandoned the invention, or

(d) the invention was first patented or caused to be patented, or was the subject of an inventor's certificate, by the applicant or his legal representatives or assigns in a foreign country prior to the date of the application for patent in this country on an application for patent or inventor's certificate filed more than twelve months before the filing of the application in the United States, or

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent, or

(f) he did not himself invent the subject matter sought to be patented, or

(g) before the applicant's invention thereof the invention was made in this country by another had not abandoned, suppressed, or concealed it. In determining priority of invention there shall be considered not only the respective dates of conception and reduction to practice of the invention, but also the reasonable diligence of one who was first to conceive and last to reduce to practice, from a time prior to conception by the other ...

Title 35, U.S. Code § 103

Conditions for patentability; non-obvious subject matter

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

Title 35, U.S. Code § 112 (in part)

Specification

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise and exact terms also enable any person skilled in the art to which it pertains, or with which it is mostly nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Title 35, U.S. Code § 119

Benefit of earlier filing date in foreign country; right of priority

An application for patent for an invention filed in this country by any person who has, or whose legal representatives or assigns have, previously regularly filed an application for a patent for the same invention in a foreign country which affords similar privileges in the case of applications filed in the United States or to citizens of the United States, shall have the same effect as the same application would have if filed in this country on the date on which the application for patent for the same invention was first filed in such foreign country, if the application in this country is filed within twelve months from the earliest date on which such foreign application was filed; but no patent shall be granted on any application for patent for an invention which had been patented or described in a printed publication in any country more than one year before the date of the actual filing of the application in this country, or which had been in public use or on sale in this country more than one year prior to such filing.

Title 35, U.S. Code § 120

Benefit or earlier filing date in the United States

An application for patent for an invention disclosed in the manner provided by the first paragraph of section 112 of this title in an application previously filed in the United States, or as provided by section 363 of this title, which is filed by an inventor or inventors named in the previously filed application shall have the same effect, as to such invention, as though filed on the date of the prior application, if filed before the patenting or abandonment of or termination of proceedings on the first application or an application similarly entitled to the benefit of the filing date of the first application and if it contains or is amended to contain a specific reference to the earlier filed application.

Please read carefully before signing the Declaration attached to the accompanying Application.

If you have any questions, please contact Morgan & Finnegan, L.L.P.

FORM:COMB-DEC.NY

Rev. 5/21/98